RECOMBINANT PRODUCTION OF SAPORIN-CONTAINING PROTEINS

Abstract: Methods for the recombinant production of saporin-containing proteins, including cell surface binding protein-saporin fusion proteins, are provided. The resulting fusion proteins are cytotoxic to targeted cells. In preferred embodiments, methods are provided for the production of basic fibroblast factor (bFGF)-saporin fusion proteins by culturing Escherichia coli that has been transformed with a vector containing DNA encoding bFGF linked via a spacer peptide to the amino terminus of a cytotoxic portion of a saporin polypeptide to obtain expression of the DNA, and isolating the resulting FGF-saporin fusion protein. FGF-saporing fusion proteins and saporin proteins containing from about 5 to 12 amino acid N-terminal extensions are also provided.

Description: RECOMBINANT PRODUCTION OF SAPORIN-CONTAINING PROTEINS This application is a continuation-in-part of United States Application Serial No. 07/901 ,718, filed June 16, 1992, by Douglas A Lappi, Isabel Barthelemy, and Andrew J. Baird entitled "RECOMBINANT PRODUCTION OF SAPORIN-CONTAINING PROTEINS". The disclosure of United States Application Serial No. 07/901 ,718 is incorporated herein in its entirety by reference. FIELD OF THE INVENTION The present invention relates to the recombinant production of proteins and more particularly to the recombinant production of saporin and saporin-containing fusion proteins. BACKGROUND OF THE INVENTION Ribosome-inactivating-proteins (RIPs) are plant proteins that catalyticaliy inactivate eukaryotic ribosomes. RIPS have been shown to inactivate ribosomes by interfering with the protein elongation step of protein synthesis. For example, the RIP saporin (SAP) has been shown to inactivate 60S ribosomes by cleavage of the n-glycosidic bond of the adenine at position 4324 in the rat 28S ribosomal RNA (rRNA). This particular region in which A 4324 is located in the rRNA is highly conserved among prokaryotes and eukaryotes. A 4324 in 28S rRNA corresponds to A 2ββ0 in Escherichia coli (E. coli) 23S rRNA. Several RIP's also appear to interfere with protein synthesis in prokaryotes, such as E fioK. Since RIPs are toxic to eukaryotic cells and some RIPs are toxic to prokaryotes (see, e.g.. Habuka et aL (1990) J. Biol. Chem. 265.10988-10992). they are difficult to express using recombinant DNA methodologies. Several structurally related RIP's have been isolated from seeds and leaves of the plant Saponaria officinalis (soapwort) . Among these, saporin-6 is the most active and abundant, representing 7% of total seed proteins. Saporin is very stable, has a high isoelectric point, does not contain carbohydrates, and is resistant to denaturing agents, such as SDS, and a variety of proteases. The amino acid sequences of several saporin-6 isoforms from seeds are known and there appear to be families of saporin RIPs differing in few amino acid residues. Because saporin is a type I RIP, it does not possess a cell-binding chain, like the toxins ricin and abrin. Consequently, its toxicity to whole cells is much lower than the toxins. When targeted to cells so that it is internalized by the cells, however, its cytotoxicity is 100- to 1000-fold more potent than ricin A chain. Because of its cytotoxicity, saporin has been covalently linked to cell surface binding ligands to produce cytotoxic chemical-conjugates or linked to antibodies to produce immunotoxins that are targeted to, and internalized by, specific cells (see, e.g.. Soria (1989) Pharmacological Res. 21 (SUDD 2):35-46. at 36). For example, basic fibroblast growth factor (bFGF) has been chemically conjugated to saporin-6 to produce the mitoxin FGF-SAP (see, e.g.. U.S. Patent No. 5,191 ,067 to Lappi et aL; and Lappi §t aL. (1989) Biochem. and Biophys. Res. Comm. 160:917-923). FGF-saporin conjugates have been used to treat restinosis (see, e.g.. International Patent Application No. WO 92/11872, which is based in U.S. Application Serial No. 07/637,074). Treatment is effected by local or intravenous administration of a therapeutically effective amount of the FGF conjugate following, for example, balloon angioplasty. FGF-saporin conjugates also have shown promise as agents for the treatment of certain tumors. The growth of melanomas and other tumors that express receptors to which FGF binds can be inhibited by FGF-SAP (see, e.g.. International Application No. WO 92/04918, which is based on U.S. Patent Application Serial No. 07/585,319; and Beitz et aL (1992) Cancer Research 2:227- 230). An anti-human immunoglobulin heavy chain monoclonal antibody has been conjugated to saporin-6. The resulting immunotoxin is potentially useful for eliminating lymphoma and leukemia cells from human bone marrow during ex vivo treatment prior to reimplantation. Other chemical conjugates of saporin with a panel of anti-T lymphocyte monoclonal antibodies have shown promise as ex vivo agents for purging human bone marrow prior to transplantation, and as systemic therapeutic agents in patients with graft-versus-host disease and T-cell and B-cell leukemia. Presently, conjugation of saporin to cell binding ligands and antibodies has been effected chemically. Chemical conjugation, however, results in a heterogeneous population of molecules. For example, bFGF is conjugated via a cysteine residue to saporin, which is first derivatized with N- succinimdyl-3(2-pyridyldithio)propionate(SPDP). Basic FGF has at least two cysteines available for reaction with SPDP-derivatized saporin. Consequently, reaction of the bFGF with the SPDP-derivatized SAP results in an array of molecules, which probably differ with respect to biologically relevant properties and may not be ideal for in vivo applications. In view of the many potential applications for saporin-containing fusion proteins, efficient recombinant means for the direct production of uniform preparations of saporin-containing proteins would be of great value. Because of the toxic effect of saporin on E ± coli. as well as eukaryotes, recombinant production of biologically active saporin has, thus far, been elusive. DNA encoding saporin-6 has been cloned and a DNA encoding truncated form expressed in JL. coli (U.K. Patent Application GB 2216891 A to FARMITALIA). The resulting protein, however, is not cytotoxic. DNA encoding recombinant bFGF-saporin fusion proteins in which the saporin and FGF are truncated have been prepared (see, Prieto el aL. (1991 ) Ann. N.Y. Acad. Sci. 538:434-437). The resulting fusion protein, however, was subsequently found not to be cytotoxic. Therefore, it is an object herein to provide effective recombinant DNA methods for the production of cytotoxic saporin-containing proteins, including fusion proteins, in prokaryotic cells. It is also an object herein to provide bFGF-SAP conjugates that are produced by recombinant DNA methods. SUMMARY OF THE INVENTION DNA constructs encoding saporin-containing proteins are provided. The DNA encodes saporin-containing proteins. The saporin-containing proteins are made of an N-terminal extension linked to the amino terminus of a saporin protein. The saporin polypeptide includes at least as much of a saporin protein as needed for the saporin to exhibit cytoxicity or protein synthesis inhibition in selected assays. The DNA encoding saporin and DNA encoding the N-terminal extension are selected such that saporin-containing protein is cytotoxic upon internalization by selected cells. The N-terminal extension appears to render the resulting saporin- containing protein sufficiently non-cytotoxic to a host to permit recombinant expression, including translation of the saporin-containing peptide in a selected host. In some embodiments, the N-terminal extension is about two to fifteen, preferably five to twelve amino acids. The sequence of the N- terminal extension can be the same as the sequence of the native saporin polypeptide signal sequence. In other embodiments, the N-terminal extension is a ligand, such as a cell surface binding protein or antibody, that specifically interacts with proteins on the surfaces of targeted cells. The DNA encoding the ligand is linked to the DNA encoding the N-terminus of the saporin polypeptide or via one, preferably two, or more codons that encode a linking peptide or amino acid. The number of linking codons is selected such that the resulting DNA encodes a fusion protein that is cytotoxic to selected cells. The combination of the ligand and saporin is prepared as a chimera, using recombinant DNA techniques. The fusion protein molecule is designed and produced in such a way that the receptor-binding domain of the ligand moiety of the complex is available for recognition of its respective cell- surface receptor and can target the fusion protein to cells containing its respective cell-surface receptor. In a preferred embodiment, the ligand is either basic FGF or another FGF polypeptide, such as acidic FGF, that is reactive with the high affinity FGF receptor. The fusion proteins containing the ligand linked to a saporin polγptide via a peptide spacer region are also provided. The spacer region contains one or more amino acids, such that the resulting fusion protein has the desired cytotoxic activity. In preferred embodiments, the ligand is an FGF. The fusion proteins are potent cytotoxic agents and, thus, should be useful in treating a variety of FGF-mediated pathophysiological conditions, including conditions for which chemically conjugated FGF-SAP has been demonstrated to be effective. Vectors or plasmids for expression of the DNA encoding the saporin- containing proteins are also provided. Vectors or plasmids that include a selectable marker gene and an origin of replication functional in the selected host, such as a bacterial, yeast, insect or mammalian cells or the expression of the fusion proteins are provided. In preferred embodiments the plasmids are suitable for expression of heterologous proteins in prokaryotic hosts, such as JL. coli. The DNA encoding the saporin-containing protein is operatively linked to a promoter region such that the DNA is inducibly expressed in the selected host. In other preferred embodiments, the DNA construct is operatively linked to a transcription terminator that functions to terminate transcription of the DNA encoding the saporin-containing protein in the selected host. Preferred hosts are those that effect inducible expression of the DNA construct. Methods for expression of the DNA constructs that encode the saporin-containing proteins are provided . In particular, methods are provided for the production of saporin-containing proteins in E ± coli by transforming the E,. coli host cell with a plasmid containing the DNA construct encoding an N-terminal extension linked to the amino terminus of a cytotoxic portion of a saporin polypeptide to obtain expression of the DNA, and isolating the saporin-containing protein. In preferred embodiments, a DNA construct encoding saporin linked to all or a portion of its native signal sequence is inserted into a plasmid such that the DNA construct is operatively linked to a signal sequence that functions in JL coli to direct secretion of the linked peptide and is operatively linked to an inducible promoter and a terminator functional in the selected host. The plasmid is introduced into a host in which the promoter is inducibly regulated. In other preferred embodiments, the DNA constructs include encoding a saporin polypeptide is linked to DNA encoding a FGF. In most preferred embodiments, DNA constructs and methods for producing fusion proteins containing bFGF linked to saporin are provided. The fusion proteins are targeted to and are cytotoxic upon internalization by cells that contain cell surface receptors to which the bFGF in the fusion protein binds. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMEMTS Definitions Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the subject matter herein belongs. All U.S. patents and all publications mentioned herein are incorporated in their entirety by reference thereto. The amino acids, which occur in the various amino acid sequences appearing herein, are identified according to their well-known, three-letter or one-letter abbreviations. The nucleotides, which occur in the various DNA fragments, are designated with the standard single-letter designations used routinely in the art. As used herein, saporin (abbreviated herein as SAP) refers to polγpeptides having amino acid sequences found in the natural plant host Saponaria officinalis. as well as modified sequences, having amino acid substitutions, deletions, insertions or additions, which still express substantial ribosome-inactivating activity. Purified preparations of saporin are frequently observed to include several molecular isoforms of the protein. It is understood that differences in amino acid sequences can occur in saporin from different species as well as between saporin molecules from individual organisms of the same species. Thus, as used herein, a saporin polypeptide includes any of the isoforms of saporin that may be isolated from Saponaria officinalis or related species or modified form that retain cytotoxic activity. In particular, such modified saporin may be produced by modifying the DNA disclosed herein by altering one or more amino acids or deleting or inserting one or more amino acids, such as a cysteine that may render it easier to conjugate to FGF or other cell surface binding protein. Any such protein, or portion thereof, that, when conjugated to FGF as described herein, that exhibits cytoxicity in standard in vitro or in vivo assays within at least about an order of magnitude of the saporin conjugates described herein is contemplated for use herein. As used herein, saporin-containing proteins are either: (1 ) proteins that include a saporin protein and an N-terminal extension that does not confer additional biological activities on the the saporin; or (2) fusion proteins containing a saporin polypeptide and a ligand, preferably basic fibroblast growth factor (bFGF), that is reactive with a particular cell surface receptor. The resulting saporin proteins (1 ) are useful as toxins for chemical conjugation to various ligands of cell surface receptors, such as growth factors (e.g. fibroblast growth factor), hormones, antibodies, and the like. The resulting saporin-containing fusion proteins (2) are useful as cytotoxins for treating diseases, including, but not limited to, certain restinosis and cancers, such as human melanomas and human ovarian carcinomas. As used herein DNA fragment, refers to a DNA molecule that is not part of a chromosome or DNA of an organelle, other than a man-made plasmid or vector. DNA fragments can include origins of DNA replication, prokaryotic and eukaryotic genes from various sources, such as selectable marker genes, repressor genes, and any other sequence of nucleotides. The DNA fragment may be in the circular form of a plasmid vector. As used herein, a mitoxin is a cytotoxic molecule targeted to specific cells by a mitogen. As used herein, to target a saporin-containing protein means to direct it to a cell that expresses a selected receptor. Upon binding to the receptor the saporin-containing protein is internalized by the cell and is cytotoxic to the cell. As used herein, the term biologically active, or reference to the biological activity of a saporin-containing polypeptide or cytotoxicity of a saporin-containing polypeptide, refers to the ability of such polypeptide to inhibit protein synthesis by inactivation of ribosomes either in vivo or in vitro or to inhibit the growth of or kill cells upon internalization of the saporin- containing polypeptide by the cells. Preferred biologically active saporin polypeptides are those that are toxic to eukaryotic cells upon entering the cells. Such biological or cytotoxic activity may be assayed by any method known to those of skill in the art including, but not limited to, the in vitro assays that measure protein synthesis and in vivo assays that assess cytoxicity by measuring the effect of a test compound on cell proliferation or on protein synthesis. Particularly preferred, however, are assays that assess cytoxicity in targeted cells. As used herein, secretion signal refers to a peptide region within the precursor protein that directs secretion of the precursor protein from the cytoplasm of the host into the periplasmic space or into the extracellular growth medium. Such signals may be either at the amino terminus or carboxyl terminus of the precursor protein. The preferred secretion signal is linked to the amino terminus of the N-terminal extension region. As used herein, N-terminal extension, refers to a peptide region that is linked to the amino terminus of a biologically active portion of a saporin polypeptide. As demonstrated herein, the N-terminal extension serves to render the saporin polypeptide portion of the saporin-containing protein either nontoxic to the host upon expression of the protein in the host or substantially less toxic to the host than the expression of a saporin polypeptide without a N-terminal extension. N-terminal extensions having as few as 5 amino acids, and as many as 500 amino acids (or more depending on the size of the ligand used) can be employed. Presently preferred N-terminal extension regions are in the range of about 8 to 300 amino acids. Most preferred N-terminal extension regions have in the range of about 5 to about 150 amino acids. Particularly preferred N-terminal extensions encode ligands. As used herein, ligand refers to any polypeptide that is capable of binding to a cell-surface protein and is capable of facilitating the internalization of the ligand-containing fusion protein into the cell. Such ligands include growth factors, antibodies or fragments thereof, hormones, and other types of proteins. As used herein, FGF refers to polypeptides having amino acid sequences of native FGF proteins, as well as modified sequences, having amino acid substitutions, deletions, insertions or additions of the native protein but retaining the ability to bind to FGF receptors and to be internalized. Such polypeptides include, but are not limited to, FGF-1 - FGF- 9. For example, bFGF should be generally understood to refer to polypeptides having substantially the same amino acid sequences and receptor-targeting activity as that of bovine bFGF or human bFGF. It is understood that differences in amino acid sequences can occur among FGFs of different species as well as among FGFs from individual organisms or species. Reference to FGFs is also intended to encompass proteins isolated from natural sources as well as those made synthetically, as by recombinant means or possibly by chemical synthesis. FGF also encompasses muteins of FGF that possess the ability to target saporin to FGF-receptor expressing cells. Such muteins include, but are not limited to, those produced by replacing one or more of the cysteines with serine or other amino acid or by replacing any of the amino acids (see, e.g.. U.S. Patent No. 5,120,715 to Kato giaL.; U.S. Patent No. 5,175,147 to Folkman et aL; European Patent Application 510662 A to TAKEDA CHEMICAL INDUSTRIES LTD.; JP 4164096 A to TAKEDA CHEMICAL INDUSTRIES LTD) in order to, for example, retain or increase the activity or stability of the growth factor, to reduce or eliminate disulfide scrambling, or to alter glycosylation As used herein, the term "FGF receptor" is used to refer to receptors that specifically interact with FGF and transport it into the cell. Included among these are the receptors described in International Application No. WO 91 /00916, which is based on U.S. Patent Application Serial No.07/377,033; International Application No. WO 92/00999, which is based on U.S. Patent Application Serial No.07/549, 587; International Application No. WO 90/05522; and International Application No. WO 92/12948; see, also Imamura (1988) Biochem. Biophvs. Res. Comm. 155:583-590 and Moscatelli (1987) J. Cell. Phvsiol. 131 :123-130. As used herein, the term "polypeptide reactive with the FGF receptor" refers to any polypeptide that specifically interacts with FGF receptor, preferably the high-affinity FGF receptor, and is transported into the cell by virtue of its interaction with the FGF receptor. As used herein, operative linkage or operative association of heterologous DNA to regulatory and effector sequences of nucleotides, such as promoters, enhancers, transcriptional and translational stop sites, and other signal sequences, refers to the functional relationship between such DNA and such sequences of nucleotides. For example, operative linkage of heterologous DNA to a promoter refers to the physical and functional relationship between the DNA and the promoter such that the transcription of such DNA is initiated from the promoter by an RNA polymerase that specifically recognizes, binds to and transcribes the DNA in reading frame. As used herein, a promoter region refers to the portion of DNA of a gene that controls transcription of DNA to which it is operatively linked. A portion of the promoter region includes specific sequences of DNA that are sufficient for RNA polymerase recognition, binding and transcription initiation. This portion of the promoter region is referred to as the promoter. In addition, the promoter region includes sequences that modulate this recognition, binding and transcription initiation activity of the RNA polymerase. These sequences may be s acting or may be responsive to trans acting factors. Promoters, depending upon the nature of the regulation, may be constitutive or regulated. For use herein, inducible promoters are preferred. The promoters are recognized by an RNA polymerase that is expressed by the host. The RNA polymerase may be endogenous to the host or may be introduced by genetic engineering into the host, either as part of the host chromosome or on an episomal element, including a plasmid containing the DNA encoding the saporin-containing polypeptide. Most preferred promoters for use herein are tightly regulated such that, absent induction, the DNA encoding the saporin-containing protein is not expressed. As used herein, a transcription terminator region has either (a) a subsegment that encodes a polyadenylation signal and polyadenγiation site in the transcript, and/or (b) a subsegment that provides a transcription termination signal that terminates transcription by the polymerase that recognizes the selected promoter. The entire transcription terminator may be obtained from a protein-encoding gene, which may be the same or different from the gene, which is the source of the promoter. Preferred transcription terminator regions are those that are functional in E,. coli. Transcription terminators are optional components of the expression systems herein, but are employed in preferred embodiments. As used herein, FGF-mediated pathophysiological condition refers to a deleterious condition characterized by or caused by proliferation of cells that are sensitive to bFGF mitogenic stimulation. Basic FGF-mediated patho¬ physiological conditions include, but are not limited to, certaion tumors, rheumatoid arthritis, restinosis, Dupuytren's Contracture and certain complications of diabetes, such as proliferative retinopathy. As used herein, vector or plasmid refers to discrete elements that are used to introduce heterologous DNA into cells for either expression of the heterologous DNA or for replication of the cloned heterologous DNA. Selection and use of such vectors and plasmids are well within the level of skill of the art. As used herein, expression vector includes vectors capable of expressing DNA fragments that are in operative linkage with regulatory sequences, such as promoter regions, that are capable of effecting expression of such DNA fragments. Thus, an expression vector refers to a recombinant DNA or RNA construct, such as a plasmid, a phage, recombinant virus or other vector that, upon introduction into an appropriate host cell, results in expression of the cloned DNA. Appropriate expression vectors are well known to those of skill in the art and include those that are replicable in eukaryotic cells and/or prokaryotic cells and those that remain episomal or may integrate into the host cell genome. As used herein, isolated, substantially pure DNA refers to DNA fragments purified according to standard techniques employed by those skilled in the art (see, e.g.. Maniatis et aL (1982) Molecular Cloning: A Laboratorv Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY and Sambrook et aL. (1989) Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.). As used herein, expression refers to the process by which nucleic acid is transcribed into mRNA and translated into peptides, polypeptides, or proteins. If the nucleic acid is derived from genomic DNA, expression may, if an appropriate eukaryotic host cell or organism is selected, include splicing of the mRNA. As used herein, "culture" means a propagation of cells in a medium conducive to their growth, and all sub-cultures thereof. The term "subculture" refers to a culture of cells grown from cells of another culture (source culture), or any subculture of the source culture, regardless of the number of subculturings that have been performed between the subculture of interest and the source culture. As used herein, ID 50 refers to the concentration at which 50% of the cells are killed following a 72-hour incubation with a toxin, such as FGF- SAP. As used herein, ED 50 refers to the concentration of saporin-containing protein required to inhibit protein synthesis in treated cells to 50% of the protein synthesis in the absence of the protein. DNA constructs DNA constructs provided herein encode a saporin-containing protein, which includes a sequence of nucleotides encoding a saporin polypeptide and an N-termina! extension sequence linked to the amino terminus of the saporin polypeptide. Preferable saporin polypeptides include polypeptides having substantially the same amino acid sequence and ribosome-inactivating activity as that of saporin-6 (SO-6), including the four isoforms, which have heterogeneity at amino acid positions 48 and 91 (see, e.g.. Maras et aL. (1990) Biochem. Internat. 21 :631-638 and Barraet aL (1991 ) Biotechnol. AppI. Biochem. 13:48-53. Other suitable saporin polypeptides include other members of the multi-gene family coding for isoforms of saporin-type RIP's including SO-1 and SO-3 (Fordham-Skelton et aL (1990) Mol. Gen. Genet. 221:134-138, SO-2 (Fordham-Skelton et aL (1991 ) Mol. Gen. Genet. 229:460-466), SO-4 (Lappi et aL (1985 Biochem. Biophvs. Res. Commun. 129:934-942) and SO-5 (Montecucchi ≤l a (1989) Int. J. Peptide Protein Res.. 33:263-267). Presently preferred saporin polypeptides include those having substantially the same amino acid sequence as those listed in SEQ ID NOs 3-7. The isolation and expression of the DNA encoding these proteins is described in Example 1. The most preferred saporin polypeptide is listed in SEQ ID NO 3. Suitable N-terminal extension regions may be substantially neutral and lack any biological function other than rendering the saporin polypeptide nontoxic or less toxic to the host in which it is expressed. The specific amino acid makeup of the N-terminal extension region does not appear to be critical for rendering the saporin-containing protein nontoxic or less toxic to the host upon expression of the protein. In a preferred embodiment, the N-terminal extension region is susceptible to cleavage by eukaryotic intracellular proteases, either by general intracellular degradation or by site-specific proteolytic processing of a proteolytic signal sequence such that, upon internalization, the N-terminal extension region of the saporin-containing fusion protein is cleaved or degraded by a cellular eukaryotic protease, which renders the single-fragment saporin protein biologically active, resulting in cell death (see, e.g.. European Patent Application EP 0466 222, for a description of suitable site-specific proteolytic signal sequences). In addition to rendering the saporin polypeptide non-toxic or less toxic to the host cell, suitable N-terminal extension regions may also serve to confer other biological functions to the saporin-containing protein after it has been isolated. In one embodiment, the N-terminal extension region contains a ligand, preferably bFGF, capable of targeting the saporin polypeptide to a specific cell, in vivo and in vitro, whereby saporin-containing protein is internalized and rendered cytotoxic to the targeted cell. Exemplary ligands include, but are not limited to, those ligands that have previously proven successful in chemical conjugates with saporin such as basic fibroblast growth factor (bFGF), purified human diferric transferrin, and the antigen binding domains of antibodies, Fab fragments (see, e.g.. Better et aL (1989) Meth. Enz. 178:476-496). such as anti-human immunoglobulin heavy chain monoclonal antibodies and anti-Thy 1 monclonal antibodies. Other ligands, include the cell surface binding domains of anti-T lymphocyte monoclonal antibodies, such as, but not limited to, anti-CD5 T- cell surface antigen, anti-CD19 and anti-CD22, anti-CD3, and anti-CD2. Particularly preferred ligands are fibroblast growth factors (FGFs), platelet- derived growth factor (PDGF), vascular endothelial cell growth factor (VEGF), and granulocyte-macrophage colony stimulating factor (GM-CSF). The most preferred ligand is bFGF. Other ligands may include, but are not limited to, those that have previously proven successful linked to other toxins, such as anti-human transferrin receptor monoclonal antibodies, alpha-melanocyte-stimulating hormone, IL-2, IL-6, transforming growth factor-type alpha (TGF-alpha), and the HIV-binding domain of the human CD4 molecule, and the like. In preferred embodiments, DNA encoding the saporin polypeptide is linked to DNA encoding an FGF polypeptide. The DNA encoding the FGF polypeptide is modified in order to remove the translation stop codon and other transcriptional or translational stop signals that may be present. The DNA is then ligated to the DNA encoding the saporin polypeptide. The DNA may include a spacer region of one or more codons between the first codon of the saporin and the last codon of the FGF. The size of the spacer region is any length as long as the resulting conjugate exhibits cytotoxic activity upon internalization by a target cell. Presently, spacer regions of from about two to about twelve codons are preferred. DNA encoding FGFs and/or the amino acid sequences of FGFs are known to those of skill in this art. DNA encoding human acid FGF (Jaye et -_ __. (1986) Science 233:541-545). bovine bFGF (Abraham el al. (1986) Science 233:545-548), human bFGF (Abraham el a (1986) EMBO J. 5_:2523-2528; and Abraham et al. (1986) Quant. Biol. 51 :657-668) and rat bFGF (see Shimasaki §1 aL (1988) Biochem. Biophvs. Res. Comm. and Kurokawa el aL (1988) Nucleic Acids Res. 16:5201 ) are known (see, also, U.S. Patent No. 5,155,214; U.S. Patent No. 4,956,455; U.S. Patent No. 5,026,839; and U.S. Patent No. 4,994,559). The amino acid sequence of an exemplary mammalian bFGF isolated from bovine pituitary tissue is also known (see, e.g.. in Esch et aL (1985) Proc.Natl. Acad. Sci. USA 82:6507-651 1 ; and U.S. Patent No. 4,956,455). The isolated mammalian basic FGF protein is typically a 146-residue polypeptide having a molecular weight of about 16 kD, and a pl of about 9.6; it may be expressed with an amino terminal extension of about 9 residues so that the resulting protein has a molecular weight of about 18kD. Plasmids for expression of saporin-containing polypeptides The DNA construct is introduced into a plasmid for expression in a desired host. In preferred embodiments, the host is a bacterial host. The sequences of nucleotides in the plasmids that are regulatory regions, such as promoters and operators, are operationally associated with one another for transcription of the sequence of nucleotides that encode a saporin-containing protein. The sequence of nucleotides encoding the saporin-containing protein may also include DNA encoding a secretion signal, whereby the resulting peptide is a precursor of saporin. The resulting processed saporin protein, which if not processed such that the resulting protein is identical to a native saporin, retains the cytotoxic activity of the native saporin protein, may be recovered from the periplasmic space or the fermentation medium. In preferred embodiments the DNA plasmids also include a transcription terminator sequence. The promoter regions and transcription terminators are each independently selected from the same or different genes. The plasmids used herein preferably include a promoter in operable association with the DNA encoding the saporin-containing protein and are designed for expression of proteins in a bacterial host. It has been found that tightly regulatable promoters are preferred for expression of saporin. Suitable promoters for expression of saporin-containing proteins are widely available and are well known in the art. Inducible promoters or constitutive promoters that are linked to regulatory regions are preferred . Such promoters include, but are not limited to, the T7 phage promoter and other T7-like phage promoters, such as the T3, T5 and SP6 promoters, the trp, Ipp, and lac promoters, such as the lacUVδ, from E. coli: the P10 or polyhedron gene promoter of baculovirus/insect cell expression systems and inducible promoters from other eukaryotic expression systems. For expression of the saporin-containing proteins such promoters are inserted in a plasmid in operative linkage with a control region such as the lac operon. Preferred promoter regions are those that are inducible and functional in Ej . coli. Examples of suitable inducible promoters and promoter regions include, but are not limited to: the E coli lac operator responsive to isopropyl ?-D-thiogalactopyranoside (IPTG; see, et aLNakamura elaL (1979) Cell 18:1 109-1 1 17); themetallothioneinpromotermetal-regulatory-elements responsive to heavy-metal (e.g.. zinc) induction (see, e.g.. U.S. Patent No. 4,870,009 to Evans et aL); and the phage T7lac promoter responsive to IPTG (see Studier et al., Meth. EnzvmoL. 185: 60-89, 1990; and U.S. Patent No. 4,952,496). The plasmids also preferably include a selectable marker gene or genes that are functional in the host. A selectable marker gene includes any gene that confers a phenotype on bacteria that allows transformed bacterial cells to be identified and selectively grown from among a vast majority of untransformed cells. Suitable selectable marker genes for bacterial hosts, for example, include the ampicillin resistance gene (Amp r ), tetracycline resistance gene (Tc r ) and the kanamycin resistance gene (Kan r ). The kanamycin resistance gene is presently preferred. The preferred plasmids also include DNA encoding a signal for secretion of the operably saporin-containing protein. Secretion signals suitable for use are widely available and are well known in the art. Prokaryotic and eukaryotic secretion signals functional in JL coJi may be employed. The presently preferred secretion signals include, but are not limited to, those encoded by the following . cojj genes: ompA, ompT, ompF, ompC, beta-lactamase, and alkaline phosphatase, and the like (von Heijne (1985) J. Mol. Biol. 184:99-105). In addition, the bacterial pelB gene secretion signal (Lei et aJL (1987) J. Bacteriol. 169:4379. 1987), the phoA secretion signal, and the cek2 functional in insect cell may be employed. The most preferred secretion signal is the E,. coli ompA secretion signal. Other prokaryotic and eukaryotic secretion signals known to those of skill in the art may also be employed (see, e.g.. von Heijne (1985) J. Mol. Biol. 184:99-105). Using the methods described herein, one of skill in the art can substitute secretion signals that are functional in either yeast, insect or mammalian cells to secrete saporin-containing proteins from those cells. Particularly preferred plasmids for transformation of JL c jj cells include the pET expression vectors (see, U.S patent 4,952,496; available from NOVAGEN, Madison, Wl). Such plasmids include pET 11 a, which contains the T7lac promoter, T7 terminator, the inducible J coii lac operator, and the lac repressor gene; and pET 12a-c, which contain the T7 promoter, T7 terminator, and the E coJi ompT secretion signal. Other preferred plasmids include the pIN-lllompA plasmids (see, U.S. Patent No. 4,575,013 to Inouye; see, also, Duffaud et aL (1987) Meth. Enz. 153:492-507), such as plN-lllompA2 . The pIN-lllompA plasmids include an insertion site for the heterologous DNA (the DNA encoding a saporin- containing protein) linked for transcriptional expression in reading phase with four functional fragments derived from the lipoprotein gene of JL coli. The plasmids also include a DNA fragment coding for the signal peptide of the ompA protein of ^ coli. positioned such that the desired polypeptide is expressed with the ompA signal peptide at its amino terminus, thereby allowing efficient secretion across the cytoplasmic membrane. The plasmids further include DNA encoding a specific segment of the E. coli lac promoter-operator, which is positioned in the proper orientation for transcriptional expression of the desired polypeptide, as well as a separate functional E coN lacl gene encoding the associated repressor molecule that, in the absence of lac operon inducer, interacts with the lac promoter-operator to prevent transcription therefrom. Expression of the desired polypeptide is under the control of the lipoprotein (Ipp) promoter and the lac promoter-operator, although transcription from either promoter is normally blocked by the repressor molecule. The repressor is selectively inactivated by means of an inducer molecule thereby inducing transcriptional expression of the desired polypeptide from both promoters. As described above, a preferred embodiment calls for the incorporation of a bFGF ligand within the N-terminal extension region of the fusion protein. The most preferred bFGF coding region is set forth in SEQ ID NO 12, nucleotides 1-465. Another preferred coding region is set forth in SEQ ID NO 13, nucleotides 1 - 465. In addition to basic FGF (bFGF) and acidic FGF (aFGF), there are known to be a number of other proteins exhibiting basic FGF mitogenic activity mediated through binding to an FGF receptor. Other FGF proteins in addition to aFGF include JdST, INT/2. FGF-5, FGF-6, KGF(FGF-7), FGF-8, and FGF-9 (see, e^, Baird et aL (1989) Brit. Med. Bull 45:438-452; Tanaka el aL (1992) Proc. Natl. Acad. Sci. USA 89:8928-8932). All of the FGF proteins induce mitogenic activity in a wide variety of normal diploid mesoderm-derived and neural crest-derived cells. A test of such "FGF mitogenic activity" is the ability to stimulate proliferation of cultured bovine aortic endothelial cells, as described in Gospodarowicz el aL (1982) J. Biol. Chem.. 257. 12266-12278 Gospodarowicz el aL ( 1976) Proc. Natl. Acad. Sci. USA 73:4120-4124. In a preferred embodiment, the DNA fragment is replicated in bacterial cells, preferably in JL coli. The preferred DNA fragment also includes a bacterial origin of replication, to ensure the maintenance of the DNA fragment from generation to generation of the bacteria. In this way, large quantities of the DNA fragment can be produced by replication in bacteria. Preferred bacterial origins of replication include, but are not limited to, the fl-ori and col E1 origins of replication. Preferred hosts contain chromosomal copies of DNA encoding T7 RNA polymerase operably linked to an inducible promoter, such as the lacUV promoter (see, U.S. Patent No. 4,952,496). Such hosts include, but are not limited to, lysogens E___, coh strains HMS174(DE3)pLysS, BL21 (DE3)pLysS, HMS174(DE3) and BL2KDE3). Strain BL2KDE3) is preferred. The pLys strains provide low levels of T7 lysozyme, a natural inhibitor of T7 RNA polymerase. The DNA fragments provided optionally further contain a gene coding for a repressor-protein. The repressor-protein is capable of repressing the transcription of a promoter that contains sequences of nucleotides to which the repressor-protein binds. The promoter can be derepressed by altering the physiological conditions of the cell. The alteration can be accomplished by the addition to the growth medium of a molecule that inhibits, for example, the ability to interact with the operator or with regulatory proteins or other regions of the DNA or by altering the temperature of the growth media. Preferred repressor-proteins include, but are not limited to the JL coh. lad repressor responsive to IPTG induction, the temperature sensitive cl857 repressor, and the like. The I coli lad repressor is preferred. The resulting bFGF-fusion proteins are highly cytotoxic when internalized by targeted cells. Host cells for expression of saporin-containing polypeptides Host organisms include those organisms in which recombinant production of heterologous proteins have been carried out, such as, but not limited to, bacteria (for example, E. coli). yeast (for example, Saccharomyces cerevisiae and Pichia pastoris). mammalian cells, insect cells. Presently preferred host organisms are strains of bacteria. Most preferred host organisms are strains of Ej. coli. Methods for Recombinant SAP production: The DNA encoding saporin-containing protein is introduced into a plasmid in operative linkage to an appropriate promoter for expression of polypeptides in a selected host organism. The DNA fragment encoding the biologically active saporin polypeptide may also include a protein secretion signal that functions in the selected host to direct the mature polypeptide into the periplasm or culture medium. The resulting saporin-containing protein can be purified by methods routinely used in the art, including, methods described hereinafter in the Examples. Methods of transforming suitable host ceϋs, preferably bacterial cells, and more preferably E. coli cells, as well as methods applicable for culturing said cells containing a gene encoding a heterologous protein, are generally known in the art. See, for example, Sambrook el aL (1989) Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. The DNA construct encoding the saporin-containing protein is introduced into the host cell by any suitable means, including, but not limited to transformation employing plasmids, viral, or bacterial phage vectors, transfection, electroporation, lipofection, and the like. The heterologous DNA can optionally include sequences, such as origins of replication that allow for the extrachromosomal maintenance of the saporin- containing plasmid, or can be designed to integrate into the genome of the host (as an alternative means to ensure stable maintenance in the host). Positive transformants can be characterized by Southern blot analysis (Sambrook el aL (1989) Molecular Cloning: A Laboratorv Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY) for the site of DNA integration; Northern blots for inducible-promoter-responsive saporin gene expression; and product analysis for the presence of saporin-containing proteins in either the cytoplasm, periplasm, or the growth media. Once the saporin-containing DNA fragment has been introduced into the host cell, the desired saporin-containing protein is produced by subjecting the host cell to conditions under which the promoter is induced, whereby the operatively linked DNA is transcribed. In a preferred embodiment, such conditions are those that induce expression from the JL coli lac operon. The plasmid containing the DNA encoding the saporin- containing protein also includes the lac operator (O) region within the promoter and may also include the lac I gene encoding the lac repressor protein (see, e.g.. Muller-Hill et aL (1968) Proc. Natl. Acad. Sci. USA 59:1259-12649). The lac repressor represses the expression from the lac promoter until induced by the addition of IPTG in an amount sufficient to induce transcription of the DNA encoding the saporin-containing protein. The expression of saporin in E coli is, thus accomplished in a two- stage process. In the first stage, a culture of transformed E___ coN cells is grown under conditions in which the expression of the saporin-containing protein within the transforming plasmid, preferably pOMPAG4, is repressed by virtue of the lac repressor. In this stage cell density increases. When an optimum density is reached, the second stage commences by addition of IPTG, which prevents binding of repressor to the operator thereby inducing the lac promoter and transcription of the saporin-encoding DNA. In a preferred embodiment, the promoter is the T7 RNA polymerase promoter, which may be linked to the lac operator and the JL coli host strain includes DNA encoding T7 RNA polymerase operably linked to the lac operator and a promoter, preferably the lacUVδ promoter. Addition of IPTG induces expression of the T7 RNA polymerase and the T7 promoter, which is recognized by the T7 RNA polymerase. In more preferred embodiments, the DNA construct includes a transcription terminator that is recognized by T7 RNA polymerase. Transformed strains, which are of the desired phenotype and genotype, are grown in fermentors by suitable methods well known in the art. In the first, or growth stage, expression hosts are cultured in defined minimal medium lacking the inducing condition, preferably IPTG. When grown in such conditions, heterologous gene expression is completely repressed, which allows the generation of cell mass in the absence of heterologous protein expression. Subsequent to the period of growth under repression of heterologous gene expression, the inducer, preferably IPTG, is added to the fermentation broth, thereby inducing expression of any DNA operatively linked to an IPTG-responsive promoter (a promoter region that contains lac operator). This last stage is the induction stage. In a preferred embodiment, the expressed saporin-containing protein is isolated from either the cytoplasm, periplasm, or the cell culture media. More preferably, the expressed saporin-containing protein is isolated as a secreted entity from either the periplasm or the culture medium. Most preferred, is the isolation of the saporin containing product from the periplasm. The resulting saporin-containing protein can be suitably isolated from the other fermentation products by methods routinely used in the art, e.g.. using a suitable affinity column as described in Example 1.E-F and 2.D; precipitation with ammonium sulfate; gel filtration; chromatography, preparative flat-bed iso-electric focusing; gel electrophoresis, high performance liquid chromatography (HPLC); and the like. Methods of isolating saporin are described in Lappi et al., Biochem. Biophys. Res. Commun.. 129:934-942. ln practicing the methods herein, an EcoR I fragment encoding the entire mature SAP polypeptide and fifteen amino acids of the saporin signal sequence has been inserted into the periplasmic secretion vector pIN- HlompA2 such that the DNA encoding the saporin signal sequence and saporin protein was operatively linked to the DNA encoding the ompA leader to produce plasmid pOMPAG4, which was introduced in E ± coli host cells. Upon induction of expression of the DNA encoding saporin-containing protein, saporin-containing polypeptide was isolated from the periplasm and cytoplasm. The saporin-containing polypeptide has been purified by immunoaffinity chromatography. Amino acid sequence analysis of the periplasmic protein indicated that the ompA signal was properly processed and that from three to ten amino acids of the native signal sequence were also removed. Similar analysis of the cytoplasmic protein indicated that the entire native signal peptide and an additional two amino acids were removed. DNA encoding full-length bFGF has been linked to DNA encoding the mature saporin protein and introduced into the pET vectors, pET-1 1 a and pET-12a expression vectors (NOVAGEN, Madison, Wl), for intracellular and periplasmic expression, respectively, of FGF-SAP fusion proteins. The resulting fusion proteins exhibit cytotoxic activity and appear to be at least as potent as the chemically conjugated FGF-SAP preparations. The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention. EXAMPLE 1 RECOMBINANT PRODUCTION OF SAPORIN-CONTAINING PROTEIN A. General Descriptions 1. Bacterial Strains: coii strain JA221 (Ipp " hdsM -i- trpE5 leuB6 lacY recA1 F'[lacl q lac + pro + J) is publicly available from the American Type Culture Collection (ATCC), Rockville, MD 20852, under the accession number ATCC 33875. (JA221 is also available from the Northern Regional Research Center (NRRL), Agricultural Research Service, U.S. Department of Agriculture, Peoria, IL 61604, under the accession number NRRL B-1521 1 ; see, also, U.S. Patent No. 4,757,013 to Inouye; and Nakamura ei aL (1979) CeM 18:1109-11 17). Strain INV1σ is commercially available from Invitrogen, San Diego, CA. 2. DNA Manipulations The restriction and modification enzymes employed herein are commercially available in the U.S. Native saporin and rabbit polyclonal antiserum to saporin were obtained as previously described in Lappi et aL Biochem. Biophvs. Res. Comm.. 129: 934-942. Ricin A chain is commercially available from SIGMA, Milwaukee, Wl. Antiserum was linked to Affi-gel 10 (BIO-RAD, Emeryville, CA) according to the manufacturer's instructions. The sequencing of the different constructions was done using the Sequenase kit of United States Biochemical Corporation (version 2.0) according to the manufacturer's instructions. Minipreparation and maxipreparations of plasmids, preparation of competent cells, transformation, M13 manipulation, bacterial media, Western blotting, and ELISA assays were according to Sambrook el aL (J. Sambrook, E.F. Fritsch and T. Maniatis. (1989) Molecular Cloning: A Laboratorv Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY). The purification of DNA fragments was done using the Geneclean II kit (Bio 101 ) according to the manufacturer's instructions. SDS gel electrophoresis was performed on a Phastsystem (Pharmacia). Western blotting was accomplished by transfer of the electrophoresed protein to nitrocellulose using the PhastTransfer system, as described by the manufacturer. The antiserum to SAP was used at a dilution of 1 :1000. Horseradish peroxidase labelled anti-lgG was used as the second antibody (see Davis el aL (1986) Basic methods in molecular biology. New York, Elsevier Science Publishing Co., pp 1-338). B. Isolation of DNA encoding saporin 1. Isolation of genomic DNA and preparation of polymerase chain reaction (PCR) primers Saponaria officinalis leaf genomic DNA was prepared as described in Bianchi et al. (1988) Plant Mol. Biol. 1 1 :203-214. Primers for genomic DNA amplifications were synthesized in a 380B automatic DNA synthesizer. The primer corresponding to the "sense" strand of saporin (SEQ ID NO 1 ) includes an EcoR I restriction site adapter immediately upstream of the DNA codon for amino acid -15 of the native saporin N-terminal leader sequence (SEQ ID NO 1 ): 5'-CTGCAGAATTCGCATGGATCCTGCTTCAAT-3'. The primer corresponding to the "antisense" strand of saporin (SEQ ID NO 2) complements the coding sequence of saporin starting from the last 5 nucleotides of the DNA encoding the carboxyl end of the mature peptide, introduces a translation stop codon after the sequence encoding mature saporin and introduces an EcoR I restriction site downstream of the saporin- encoding DNA and the introduced stop codon (SEQ ID NO 2): 5'- CTGCAGAATTCGCCTCGTTTGACTAC TTTG-3'. 2. PCR to amplify DNA encoding saporin Unfractionated Saponaria officinalis leaf genomic DNA (1 μ\) was mixed in a final volume of 100 //I containing 10 mM Tri-HCI (pH 8.3), 50 mM KCI, 0.01 % gelatin, 2 mM MgCI 2 , 0.2 mM dNTPs, 0.8 μg of each primer. Next, 2.5 U Taql DNA polymerase (Perkin Elmer Cetus) was added and the mixture was overlaid with 30 μ\ of mineral oil (Sigma). Incubations were done in a DNA Thermal Cycler (Perkin Elmer Cetus). One cycle included a denaturation step (94°C for 1 min.), an annealing step (60°C for 2 min.), and an elongation step (72°C for 3 min.). After 30 cycles, a 10 μ\ aliquot of each reaction was run on a 1.5% agarose gel to verify the correct structure of the amplified product. The amplified DNA was digested with EcoR I and subcloned into EcoR l-restricted M13mp18 (NEW ENGLAND BIOLABS, Beverly, MA; see, also, Yanisch-Perron gi aL (1985), "Improved M13 phage cloning vectors and host strains: Nucleotide sequences of the M13mp18 and pUC19 vectors", Gene 33:103). Single-stranded DNA from recombinant phages was sequenced using oligonucleotides based on internal points in the coding sequence of saporin (see, Bennati el aL (1989) Eur. J. Biochem. 183:465- 470). Nine of the M13mp18 derivatives were sequenced and compared. Of the nine sequenced clones, five had unique sequences, set forth as SEQ ID NOs 3-7, respectively. The clones were designated M13mp18-G4, -G1 , -G2, -G7, and -G9. Each of these clones contains ail of the saporin coding sequence and 45 nucleotides of DNA encoding the native saporin N-terminal leader peptide. C. pOMPAG4 Plasmid Construction: M13 mp18-G4, containing the SEQ ID NO 3 clone from Example 1.B.2., was digested with EcoR I, and the resulting fragment was ligated into the EcoR I site of the vector plN-lllompA2 (see, e.g.. see, U.S. Patent No. 4,575,013 to Inouye; and Duffaud el aL (1987) Meth. Enz. 153:492- 507) using the methods described in Example 1.A.2. The ligation was accomplished such that the DNA encoding saporin, including the N-terminal extension, was fused to the leader peptide segment of the bacterial ompA gene. The resulting plasmid pOMPAG4 contains the Ipp promoter [Nakamura, K. and Inouye, M. Cell.. 18:1109-1 1 17 (1979)], the E. coli lac promoter operator sequence (lac O) and the E___ coJi ompA gene secretion signal in operative association with each other and with the saporin and native N-terminal leader-encoding DNA listed in SEQ ID NO 3. The plasmid also inlcudes the E_, c JJ lac repressor gene (lac I). The M13 mp18-G1 , -G2, -G7, and -G9 clones obtained from Example 1.B.2, containing SEQ ID NOs 4-7 respectively, are digested with EcoR I and ligated into EcoR I digested plN-lllompA2 as described for M13 mp18-G4 above in this example. The resulting plasmids, labeled pOMPAGI , pOMPAG2, pOMPAG7, pOMPA9, are screened, expressed, purified, and characterized as described for the plasmid pOMPAG4. INV1 a competent cells were transformed with pOMPAG4 and cultures containing the desired plasmid structure were grown further in order to obtain a large preparation of isolated pOMPAG4 plasmid using methods described in Example 1.A.2. D. Saporin expression in E coli: The pOMPAG4 transformed E. COH cells were grown under conditions in which the expression of the saporin-containing protein is repressed by the lac repressor to an O.D. in or at the end of the log phase of growth after which IPTG was added to induce expression of the saporin-encoding DNA. To generate a large-batch culture of pOMPAG4 transformed E^. coii cells, an overnight culture (lasting approximately 16 hours) of JA221 E. coli cells transformed with the plasmid pOMPAG4 in LB broth (see e.g.. Sambrook et aL (1989) Molecular Cloning: A Laboratorv Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY) containing 125 mg/ml ampicillin was diluted 1 :100 into a flask containing 750 ml LB broth with 125 mg/ml ampicillin. Cells were grown at logarithmic phase shaking at 37°C until the optical density at 550 nm reached 0.9 measured in a spectrophotometer. In the second step, saporin expression was induced by the addition of IPTG (Sigma) to a final concentration of 0.2 mM. Induced cultures were grown for 2 additional hours and then harvested by centrifugation (25 min., 6500 x g). The cell pellet was resuspended in ice cold 1.0 M TRIS, pH 9.0, 2mM EDTA (10 ml were added to each gram of pellet). The resuspended material was kept on ice for 20-60 minutes and then centrifuged (20 min., 6500 x g) to separate the periplasmic fraction of E. coli. which corresponds to the supernatant, from the intracellular fraction corresponding to the pellet. E. Purification of recombinant Saporin secreted to periplasm: 1. Anti-SAP immuno-affinity purification The periplasmic fraction from Example 1.D. was dialyzed against borate-buffered saline (BBS: 5 mM boric acid, 1.25 mM borax, 145 mM sodium chloride, pH 8.5). The dialysate was loaded onto an immunoaffinity column (0.5 x 2 cm) of anti-saporin antibodies, obtained as described in Lappi et aL, Biochem. Biophvs. Res. Comm., 129: 934-942 (1985), bound to Affi-gel 10 and equilibrated in BBS at a flow rate of about 0.5 ml/min. The column was washed with BBS until the absorbance at 280 nm of the flow-through was reduced to baseline. Next the column containing the antibody bound saporin was eluted with 1.0 M acetic acid and 0.5 ml fractions were collected in tubes containing 0.3 ml of 2 M ammonium hydroxide, pH 10. The fractions were analyzed by ELISA (see, e.g.. Sambrook el aL (1989) Molecular Cloning: A Laboratorv Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY) . The peak fraction of the ELISA was analyzed by Western blotting as described in Example 1.A.2 and showed a single band with a slightly higher molecular weight than native saporin. The fractions that contained saporin protein, as determined by the ELISA, were then pooled for further purification. 2. Reverse Phase High Performance Liquid Chromatography purification To further purify the saporin secreted into the periplasm, the pooled fractions from Example 1.E.I . were diluted 1 :1 with 0.1 % trifluoroacetic acid (TFA) in water and chromatographed in reverse phase high pressure liquid chromatography (HPLC) on a Vydac C4 column (Western Analytical) equilibrated in 20% acetonitrile, 0.1 % TFA in water. The protein was eluted with a 20 minute gradient to 60% acetonitrile. The HPLC produced a single peak that was the only area of immunoreactivity with anti-SAP antiserum when analyzed by a western blot as described in Example 1.E.I . Samples were assayed by the ELISA . Sequence analysis was performed by Edman degradation in a gas-phase sequenator (Applied Biosystems) as described in Lappi et al., Biochem. Biophvs. Res. Comm.. 129: 934-942 (1985). The results indicated that five polypeptides were obtained that differ in the length, between 7 and 12 amino acids, of the N-terminal saporin leader before the initial amino acid valine of the mature native saporin (SEQ ID NO 3: residue -12 through -7). All of the N-terminal extended variants retained cytotoxic activity. The size of the native lader is 18 residues, indicating that the native signal peptide is not properly processed by bacterial processing enzymes. The ompA signal was, however, properly processed. F. Purification of intracellular soluble saporin To purify the cytosolic soluble saporin protein, the pellet from the intracellular fraction of Example 1.E. above was resuspended in lysis buffer (30 mM TRIS, 2 mM EDTA, 0.1 % Triton X-100, pH 8.0, with 1 mM PMSF, 10 /g/ml pepstatin A, 10 μg aprotinin, μg/ml leupeptin and 100 /g/ml lysozyme, 3.5 ml per gram of original pellet). To lyse the cells, the suspension was left at room temperature for one hour, then frozen in liquid nitrogen and thawed in a 37°C bath three times, and then sonicated for two minutes. The lysate was centrifuged at 1 1 ,500 x g for 30 min. The supernatant was removed and stored. The pellet was resuspended in an equal volume of lysis buffer, centrifuged as before, and this second supernatant was combined with the first. The pooled supernatants were dialyzed versus BBS and chromatographed over the immunoaffinity column as described in Example 1.E.I . This material also retained cytotoxic activity. G. Assay for cytotoxic activity The RIP activity of recombinant saporin was compared to the RIP activity of native SAP in an in vitro assay measuring cell-free protein synthesis in a nuclease-treated rabbit reticulocyte lysate (Promega). Samples of immunoaffinity-purified saporin, obtained in Example 1.E.1., were diluted in PBS and 5 μ\ of sample was added on ice to 35 μ\ of rabbit reticulocyte lysate and 10 μ\ of a reaction mixture containing 0.5 μ\ of Brome Mosaic Virus RNA, 1 mM amino acid mixture minus leucine, 5 μC\ of tritiated leucine and 3 μ\ of water. Assay tubes were incubated 1 hour in a 30°C water bath. The reaction was stopped by transferring the tubes to ice and adding 5 μ\ of the assay mixture, in triplicate, to 75 μ\ of 1 N sodium hydroxide, 2.5% hydrogen peroxide in the wells of a Millititer HA 96-well filtration plate (Millipore). When the red color had bleached from the samples, 300 μ\ of ice cold 25% trichloroacetic acid (TCA) were added to each well and the plate left on ice for another 30 min. Vacuum filtration was performed with a Millipore vacuum holder. The wells were washed three times with 300 μ\ of ice cold 8% TCA. After drying, the filter paper circles were punched out of the 96-well plate and counted by liquid scintillation techniques. The IC 50 for the recombinant and native saporin were approximately 20 pM. Therefore, recombinant saporin-containing protein has full protein synthesis inhibition activity when compared to native saporin. EXAMPLE 2 RECOMBINANT PRODUCTION OF FGF-SAP FUSION PROTEIN A. General Descriptions 1. Bacterial Strains and Plasmids: coii strains BL2KDE3), BL21 (DE3)pLysS, HMS174(DE3) and HMS174(DE3)pLysS were purchased from NOVAGEN, Madison, Wl. Plasmid pFC80, described below, has been described in the WIP0 Interational Patent Application No. WO 90/02800, except that the bFGF coding sequence in the plasmid designated pFC80 herein has the sequence set forth as SEQ ID NO 12, nucleotides 1-465. The plasmids described herein may be prepared using pFC80 as a starting material or, alternatively, by starting with a fragment containg the CH ribosome binding site (SEQ ID NO 15) linked to the FGF-encoding DNA (SEQ ID NO 12). 2. DNA Manipulations The restriction and modification enzymes employed here are commercially available in the U.S. Native SAP, chemically conjugated bFGF- SAP and rabbit polyclonal antiserum to SAP and FGF were obtained as described in Lappi et al., Biochem. Biophvs. Res. Comm., 129: 934-942 (1985) and Lappi et al., Biochem. Biophvs.. Res. Comm.. 160: 917-923 (1989). The pET System Induction Control was purchased from NOVAGEN, Madison, Wl. The sequencing of the different constructions was done using the Sequenase kit of United States Biochemical Corporation (version 2.0). Minipreparation and maxipreparations of plasmids, preparation of competent cells, transformation, M13 manipulation, bacterial media and Western blotting were performed using routine methods (see, e.g...Sambrook et al. (1989) Molecular Cloning: A Laboratorv Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY). The purification of DNA fragments was done using the Geneclean II kit, purchased from Bio 101. SDS gel electrophoresis was performed on a Phastsystem (Pharmacia). B. Construction of plasmids encoding FGF-SAP fusion proteins 1. Construction of FGFM 13 that contains D A encoding the Cl ribosome binding site linked to FGF A Nco I restriction site was introduced into the SAP-encoding DNA the M13mp18-G4 clone, prepared as described in Example 1 .B.2. by site- directed mutagenesis method using the Amersham in vitro-mutagenesis system 2.1. The oligonudeotide employed to create the Nco I restriction site was synthesized using a 380B automatic DNA synthesizer (Applied Biosystems) and is listed as: SEQ ID NO 8 - CAACAACTGCCATGGTCACATC. This oligonudeotide containing the Nco I site replaced the original SAP- containing coding sequence at SEQ ID NO 3, nts 32-53. The resulting M13mp18-G4 derivative is termed mpNG4. In order to produce a bFGF coding sequence in which the stop codon was removed, the FGF-encoding DNA was subcloned into a M13 phage and subjected to site-directed mutagenesis. Plasmid pFC80 is a derivative of pDS20 (see, e.g.. Duester el aL (1982) CeN 30:855-864; see also U.S. Patent Nos. 4,914,027, 5,037,744, 5,100,784, and 5,187,261 ; see, also, PCT Internationl Application No. WO 90/02800; and European Patent Application No. EP 267703 A1 ), which is almost the same as plasmid pKG1800 (see, Bernardi fil aL (1990) DNA Seouence 1 :147-150: see, also McKenney el aL (1981 ) pp. 383-415 in Gene Amplification and Analvsis 2: Analvsis of Nucleic Acids by Enzvmatic Methods Chirikjian el aL, eds, North Holland Publishing Company, Amsterdam) except that it contains an extra 440 bp at the distal end of oalK between nucleotides 2440 and 2880 in pDS20. Plasmid pKG1800 includes the 2880 bp EcoR l-Pvu II of pBR322 that contains the contains the amplicillin rsistance gene and an origin of replication. Plasmid pFC80 was prepared from pDS20 by replacing the entire oalK gene with the FGF-encoding DNA of SEQ ID NO. 12, inserting the trp pro¬ moter (SEQ ID NO. 14) and the bacteriophage lambda CM ribosome binding site (SEQ. ID No. 15; see, e.g.. Schwarz ei §L (1978) Nature 272:410) up- stream of and operatively linked to the FGF-encoding DNA. The Trp pro¬ moter can be obtained from plasmid pDR720 (Pharmacia PL Biochemicals) or sythesized according to SEQ ID NO. 14. Plasmid pFC80, contains the 2880 bp EcoR l-BamH I fragment of plasmid pSD20, a synthetic Sal l-Nde I fragment that encodes the Trp promoter region (SEQ ID NO. 14): EcoR I AATTCCCCTGTTGACAATTAATCATCGAACTAGTTAACTAGTACGCAGCTTGGCTGCAG and the Cll ribosome binding site (SEQ ID NO.15)): Sal I Nde l GTCGACCAAGCTTGGGCATACATTCAATCAATTGTTATCTAAGGAAATACTTACATATG The FGF-encoding DNA was removed from pFC80 by treating it as follows. The pFC80 plasmid was digested by Hga I and Sai I, which produces a fragment containg the Cll ribosome binding site linked to the FGF-encoding DNA. The resulting fragment was blunt ended with Klenow's reagent and inserted into M13mp18 that had been opened by Sma I and treated with alkaline phosphatase for blunt-end ligation. In order to remove the stop codon, an insert in the ORI minus direction was mutagenized using the Amersham kit, as described above, using the following oligonudeotide (SEQ ID NO 9): GCTAAGAGCGCCATGGAGA. SEQ ID NO 9 contains 1 nucleotide between the FGF carboxy terminal serine codon and a Nco I restriction site, and it replaced the following wild type FGF encoding DNA having SEQ ID NO 10: GCT AAG AGC TGA CCA TGG AGA. Ala Lys Ser STOP Pro Trp Arg The resulting mutant derivative of M13mp18, lacking a native stop codon after the carboxy terminal serine codon of bFGF, was designated FGFM13. The mutagenized region of FGFM13 contained the correct sequence (SEQ ID NO 1 1 ). 2. Preparation of plasmids pFS92 (PZ1A), PZ1B and PZ1C that encode the FGF-SAP fusion protein a. Plasmid pFS92 (also designated PZ1A) Plasmid FGFM13 was cut with Nco I and Sac I to yield a fragment containing the Cll ribosome binding site linked to the bFGF coding sequence with the stop codon replaced. The M13mp18 derivative mpNG4 containing the saporin coding sequence was also cut with restriction endonucleases Nco I and Sac I, and the bFGF coding fragment from FGFM13 was inserted by ligation to DNA encoding the fusion protein bFGF-SAP into the M13mp18 derivative to produce mpFGF-SAP, which contains the Cll ribosome binding site linked to the FGF-SAP fusion gene. The sequence of the fusion gene is set forth in SEQ ID NO 12 and indicates that the FGF protein carboxy terminus and the saporin protein amino terminus are separated by 6 nucleotides (SEQ ID NOs 12 and 13, ntds 466-471 ) that encode two amino acids Ala Met. Plasmid mpFGF-SAP was digested with Xba I and EcoR I and the resulting fragment containing the bFGF-SAP coding sequence was isolated and ligated into plasmid pET-1 1 a (available from NOVAGEN, Madison, Wl; for a description of the plasmids see U.S. Patent No. 4,952,496; see, also Studier el aL (1990) Meth. Enz. 185:60-89: Studier el aL (1986) J. Mol. Biol. 189: 1 13-130; Rosenberg el aL (1987) Gene 56: 125-135) that had also been treated with EcoR I and Xba I. The resulting plasmid was designated pFS92. It was renamed PZ1A. Plasmid pFS92 (or PZ1 A) contains DNA the entire basic FGF protein (SEQ ID NO 12), a 2-amino acid long connecting peptide, and amino acids 1 to 253 of the mature SAP protein. Plasmid pFS92 also includes the Cll ribosome binding site linked to the FGF-SAP fusion protein and the T7 promoter region from pET-1 1a. coii strain BL21 (DE3)pLysS (NOVAGEN, Madison Wl) was transfomed with pFS92 according to manufacturer's instructions and the methods described in Example 2.A.2. b. Plasmid PZ1B Plasmid pFS92 was digested with EcoR I, the ends repaired by adding nucleoside triphosphates and Klenow DNA polymerase, and then digested with Nde I to release the FGF-encoding DNA without the Cll ribosome binding site. This fragment was ligated into pET 11a, which had been BamH I digested, treated to repair the ends, and digested with Nde I. The resulting plasmid was designated PZ1 B. PZ1 B includes the T7 transcription terminator and the pET-1 1a ribosome binding site. E. coli strain BL2KDE3) (NOVAGEN, Madison Wl) was transfomed with PZ1 B according to manufacturer's instructions and the methods described in Example 2. A.2. c. Plasmid PZ1C Plasmid PZ1C was prepared from PZ1 B by replacing the amplicillin resistance gene with a kanamycin resistance gene. c. Plasmid PZ1D Plasmid pFS92 was digested with EcoR I and Nde I to release the FGF-encoding DNA without the Cll ribosome binding site and the and the ends were repaired. This fragment was ligated into pET 12a, which had been BamH I digested and treated to repair the ends. The resulting plasmid was designated PZ1 D. PZ1 D includes DNA encoding the OMP T secretion signal operatively linked to DNA encoding the fusion protein. E___ coN strains BL2KDE3), BL21 (DE3)pLysS, HMS174(DE3) and HMS174(DE3)pLysS (NOVAGEN, Madison Wl) were transfomed with PZ1 D according to manufacturer's instructions and the methods described in Example 2. A.2.. C. Expression of the recombinant bFGF-SAP fusion proteins The two-stage method described above was used to produce recombinant bFGF-SAP protein (hereinafter bFGF-SAP fusion protein). 1. Expression of rbFGF-SAP from pFS92 (PZ1A) Three liters of LB broth containing ampicillin (50 //g/ml) and chloramphenicol (25 //g/ml) were inoculated with pFS92 plasmid-containing bacterial cells (strain BL21 (DE3)pLysS) from an overnight culture (1 :100 dilution) that were obtained according to Example 2.B. Cells were grown at 37° C in an incubator shaker to an OD 600 of 0.7. IPTG (Sigma Chemical, St. Louis, MO) was added to a final concentration of 0.2 mM and growth was continued for 1.5 hours at which time cells were centrifuged. Subsequent experiments have shown that growing the BL21 (DE3)pLysS cells at 30° C instead of 37° C improves yields. When the cells are grown at 30° C they are grown to an OD 600 of 1.5 prior to induction. Following induction, growth is continued for about 2 to 2.5 hours at which time the cells are harvested by centrifugation. The pellet was resuspended in lysis solution (45-60 ml per 16 g of pellet; 20 mM TRIS, pH 7.4, 5 mM EDTA, 10% sucrose, 150 mM NaCl, lysozyme, 100 //g/ml, aprotinin, 10 //g/ml, leupeptin, 10 g/ml, pepstatin A, 10 //g/ml and 1 mM PMSF) and incubated with stirring for 1 hour at room temperature. The solution was frozen and thawed three times and sonicated for 2.5 minutes. The suspension was centrifuged at 12,000 X g for 1 hour; the resulting first-supernatant was saved and the pellet was resuspended in another volume of lysis solution without lysozyme. The resuspended material was centrifuged again to produce a second-supernatant, and the two supernatants were pooled and dialyzed against borate buffered saline, pH 8.3. 2. Expression of bFGF-SAP fusion protein from PZ1B and PZ1C Two hundred and fifty mis. of LB medium containing ampicillin (100 //g/ml) were inoculated with a fresh glycerol stock of PZ1 B. Cells were grown at 30° C in an incubator shaker to an OD 600 of 0.7 and stored overnight at 4° C. The following day the cells were pelleted and resuspended in fresh LB medium (no ampicillin). The cells were divided into 5 1 -liter batches and grown at 30° C in an incubator shaker to an OD 600 of 1.5. iPTG (SIGMA CHEMICAL, St. Louis, MO) was added to a final concentration of 0.1 mM and growth was continued for about 2 to 2.5 hours at which time cells were harvested by centrifugation. In order to grow PZ1 C, prior to induction, the cells are grown in meidum containing kanamycin (50//g/ml) in place of ampicillin. 3. Expression of bFGF-SAP fusion protein from PZ1D Two hundred and fifty mis of LB medium containing ampicillin (100 / g/ml) were inoculated with a fresh glycerol stock of PZ1 B. Cells were grown at 30° C in an incubator shaker to an OD 600 of 0.7 and stored overnight at 4° C. The following day the cells were pelleted and resuspended in fresh LB medium (no ampicillin). The cells were used to inoculate a 1 liter batch of LB medium and grown at 30° C in an incubator shaker to an OD β00 of 1.5. IPTG (SIGMA CHEMICAL, St. Louis, MO) was added to a final concentration of 0.1 mM and growth was continued for about 2 to 2.5 hours at which time cells were harvested by centrifugation. The cell pellet was resuspended in ice cold 1.0 M Tris pH 9.0. 2 mM EDTA. The resuspended material is kept on ice for another 20-60 minutes and then centrifuged to separate the periplasmic fraction (supernatant) from the intracellular fraction (pellet). D. Affinity purification of bFGF-SAP fusion protein Thirty ml of the dialyzed solution containing the bFGF-SAP fusion protein from Example 2.C. was applied to HiTrap heparin-Sepharose column (Pharmacia, Uppsala, Sweden) equilibrated with 0.15 M NaCl in 10 mM TRIS, pH 7.4 (buffer A). The column was washed: first with equilibration buffer; second with 0.6 M NaCl in buffer A; third with 1.0 M NaCl in buffer A; and finally eluted with 2 M NaCl in buffer A into 1 .0 ml fractions. Samples were assayed by the ELISA method. The results indicate that the bFGF-SAP fusion protein elutes from the heparin-Sepharose column at the same concentration (2 M NaCl) as native and recombinantly-produced bFGF. This indicates that the heparin affinity is retained in the bFGF-SAP fusion protein. E. Characterization of the bFGF-SAP fusion protein 1. Western blot of affinity-purified bFGF-SAP fusion protein SDS gel electrophoresis was performed on a Phastsystem utilizing 20% gels (Pharmacia). Western blotting was accomplished by transfer of the electrophoresed protein to nitrocellulose using the PhastTransfer system (Pharmacia), as described by the manufacturer. The antisera to SAP and bFGF were used at a dilution of 1 :1000 dilution. Horseradish peroxidase labeled anti-IgG was used as the second antibody (Davis el aL (1986) Basic Methods in Molecular Biology. New York, Elsevier Science Publishing Co., pp 1-338). The anti-SAP and anti-FGF antisera bound to a protein with an approximate molecular weight of 48,000 kd, which corresponds to the sum of the independent molecular weights of SAP (30,000) and bFGF (18,000). 2. Assays to assess the cytoxicity of the FGF-SAP fusion protein a. Effect of bFGF-SAP fusion protein on cell-free protein synthesis The RIP activity of bFGF-SAP fusion protein compared to the FGF-SAP chemical conjugate was assayed as described in Example 1.G. The results indicated that the IC 50 of the bFGF-SAP fusion protein is about 0.2 nM and the IC 50 of chemically conjugated FGF-SAP is about 0.125 nm. b. Cytotoxicity of bFGF-SAP fusion protein Cytotoxicity experiments were performed with the Promega (Madison, Wl) CellTiter 96 Cell Proliferation/Cytotoxicity Assay. About 1 ,500 SK-Mel-28 cells (available from ATCC), a human melanoma cell line, were plated per well in a 96 well plate in 90 μ\ HDMEM plus 10% FCS and incubated overnight at 37°C, 5% CO2. The following morning 10 μ\ of media alone or 10 μ\ of media containing various concentrations of the rbFGF-SAP fusion protein, basic FGF or saporin were added to the wells. The plate was incubated for 72 hours at 37°C. Following the incubation period, the number of living cells was determined by measuring the incorporation and conversion of the commonly available dye MTT supplied as a part of the Promega kit. Fifteen μ\ of the MTT solution was added to each well, and incubation was continued for 4 hours. Next, 100 μ\ of the standard solubilization solution supplied as a part of the Promega kit was added to each well. The plate was allowed to stand overnight at room temperature and the absorbance at 560 nm was read on an ELISA plate reader (Titertek Multiskan PLUS, ICN, Flow, Costa Mesa, CA). The results indicated that the chemical FGF-SAP conjugate has an ID 50 of 0.3 nM, the bFGF-SAP fusion protein has a similar 1D 50 of 0.6 nM, and unconjugated SAP, which is unable to bind to the cell surface, has an ID 50 of 200nM. Therefore, when internalized, the bFGF-SAP fusion protein appears to have approximately the same cytotoxic actitivy as the chemically conjugated FGF-SAP. Since modifications will be apparent to those of skill in this art, it is intended that this invention be limited only by the scope of the appended claims. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Lappi, Douglas A. Barthelemy, Isabel Baird, J. Andrew Sosnowski, Barbara A. (ii) TITLE OF INVENTION: RECOMBINANT PRODUCTION OF SAPORIN-CONTAINING PROTEINS (iii) NUMBER OF SEQUENCES: 15 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Fitch, Even, Tabin & Flannery (B) STREET: 135 South LaSalle Street, Suite 900 (C) CITY: Chicago (D) STATE: IL (E) COUNTRY: USA (F) ZIP: 60603 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 07/901,718 (B) FILING DATE: 16-JUN-1992 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Seidman, Stephanie (B) REGISTRATION NUMBER: 33,779 (C) REFERENCE/DOCKET NUMBER: 54537PCT (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 619-552-1131 (B) TELEFAX: 619-552-0095 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (ix) FEATURE: (A) NAME/KEY: misc_recomb (B) LOCATION: 6..11 (D) OTHER INFORMATION: /standard_name= "EcoRI Restriction Site" (ix) FEATURE: (A) NAME/KEY: sig_peptide (B) LOCATION: 12..30 (D) OTHER INFORMATION: /function= "N-terminal extension" /products "Native saporin signal peptide" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: CTGCAGAATT CGCATGGATC CTGCTTCAAT 30 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iv) ANTI-SENSE: YES (ix) FEATURE: (A) NAME/KEY: misc_recomb (B) LOCATION: 6..11 (D) OTHER INFORMATION: /standard_name= "EcoRI Restriction Site" (ix) FEATURE: (A) NAME/KEY: terminator (B) LOCATION: 23..25 (D) OTHER INFORMATION: /note= "Anti-sense stop codon" (ix) FEATURE: (A) NAME/KEY: mat_peptide (B) LOCATION: 26..30 (D) OTHER INFORMATION: /note= "Anti-sense to carboxyl terminus of mature peptide" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: CTGCAGAATT CGCCTCGTTT GACTACTTTG 30 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: S04 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: CDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..804 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1..804 (D) OTHER INFORMATION: /note= "Nucleotide sequence corresponding to the clone M13 mpl8-G4 in Example l.B.2." ( ix ) FEATURE : (A) NAME/KEY: mat_peptide (B) LOCATION: 46..804 (D) OTHER INFORMATION: /product= ""Saporin"" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: GCA TGG ATC CTG CTT CAA TTT TCA GCT TGG ACA ACA ACT GAT GCG GTC 48 Ala Trp lie Leu Leu Gin Phe Ser Ala Trp Thr Thr Thr Asp Ala Val -15 -10 -5 1 ACA TCA ATC ACA TTA GAT CTA GTA AAT CCG ACC GCG GGT CAA TAC TCA 96 Thr Ser lie Thr Leu Asp Leu Val Asn Pro Thr Ala Gly Gin Tyr Ser 5 10 15 TCT TTT GTG GAT AAA ATC CGA AAC AAT GTA AAG GAT CCA AAC CTG AAA 144 Ser Phe Val Asp Lys lie Arg Asn Asn Val Lys Asp Pro Asn Leu Lys 20 25 30 TAC GGT GGT ACC GAC ATA GCC GTG ATA GGC CCA CCT TCT AAA GAA AAA 192 Tyr Gly Gly Thr Asp lie Ala Val lie Gly Pro Pro Ser Lys Glu Lys 35 40 45 TTC CTT AGA ATT AAT TTC CAA AGT TCC CGA GGA ACG GTC TCA CTT GGC 240 Phe Leu Arg lie Asn Phe Gin Ser Ser Arg Gly Thr Val Ser Leu Gly 50 55 60 65 CTA AAA CGC GAT AAC TTG TAT GTG GTC GCG TAT CTT GCA ATG GAT AAC 288 Leu Lys Arg Asp Asn Leu Tyr Val Val Ala Tyr Leu Ala Met Asp Asn 70 75 80 ACG AAT GTT AAT CGG GCA TAT TAC TTC AAA TCA GAA ATT ACT TCC GCC 336 Thr Asn Val Asn Arg Ala Tyr Tyr Phe Lys Ser Glu He Thr Ser Ala 85 90 95 GAG TTA ACC GCC CTT TTC CCA GAG GCC ACA ACT GCA AAT CAG AAA GCT 384 Glu Leu Thr Ala Leu Phe Pro Glu Ala Thr Thr Ala Asn Gin Lys Ala 100 105 110 TTA GAA TAC ACA GAA GAT TAT CAG TCG ATC GAA AAG AAT GCC CAG ATA 432 Leu Glu Tyr Thr Glu Asp Tyr Gin Ser He Glu Lys Asn Ala Gin He 115 120 125 ACA CAG GGA GAT AAA AGT AGA AAA GAA CTC GGG TTG GGG ATC GAC TTA 480 Thr Gin Gly Asp Lys Ser Arg Lys Glu Leu Gly Leu Gly He Asp Leu 130 135 140 145 CTT TTG ACG TTC ATG GAA GCA GTG AAC AAG AAG GCA CGT GTG GTT AAA 528 Leu Leu Thr Phe Met Glu Ala Val Asn Lys Lys Ala Arg Val Val Lys 150 155 160 AAC GAA GCT AGG TTT CTG CTT ATC GCT ATT CAA ATG ACA GCT GAG GTA 576 Asn Glu Ala Arg Phe Leu Leu He Ala He Gin Met Thr Ala Glu Val 165 170 175 GCA CGA TTT AGG TAC ATT CAA AAC TTG GTA ACT AAG AAC TTC CCC AAC 624 Ala Arg Phe Arg Tyr He Gin Asn Leu Val Thr Lys Asn Phe Pro Asn 180 185 190 AAG TTC GAC TCG GAT AAC AAG GTG ATT CAA TTT GAA GTC AGC TGG CGT 672 Lys Phe Asp Ser Asp Asn Lys Val He Gin Phe Glu Val Ser Trp Arg 195 200 205 AAG ATT TCT ACG GCA ATA TAC GGG GAT GCC AAA AAC GGC GTG TTT AAT 720 Lys He Ser Thr Ala He Tyr Gly Asp Ala Lys Asn Gly Val Phe Asn 210 215 220 225 AAA GAT TAT GAT TTC GGG TTT GGA AAA GTG AGG CAG GTG AAG GAC TTG 768 Lys Asp Tyr Asp Phe Gly Phe Gly Lys Val Arg Gin Val Lys Asp Leu 230 235 240 CAA ATG GGA CTC CTT ATG TAT TTG GGC AAA CCA AAG 804 Gin Met Gly Leu Leu Met Tyr Leu Gly Lys Pro Lys 245 250 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 804 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: CDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..804 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1..804 (D) OTHER INFORMATION: /note= "Nucleotide sequence corresponding to the clone M13 mpl8-Gl in Example l.B.2." (ix) FEATURE: (A) NAME/KEY: mat_peptide (B) LOCATION: 46..804 (D) OTHER INFORMATION: /product= "Saporin" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: GCA TGG ATC CTG CTT CAA TTT TCA GCT TGG ACA ACA ACT GAT GCG GTC 48 Ala Trp He Leu Leu Gin Phe Ser Ala Trp Thr Thr Thr Asp Ala Val -15 -10 -5 1 ACA TCA ATC ACA TTA GAT CTA GTA AAT CCG ACC GCG GGT CAA TAC TCA 96 Thr Ser He Thr Leu Asp Leu Val Asn Pro Thr Ala Gly Gin Tyr Ser 5 10 15 TCT TTT GTG GAT AAA ATC CGA AAC AAC GTA AAG GAT CCA AAC CTG AAA 144 Ser Phe Val Asp Lys He Arg Asn Asn Val Lys Asp Pro Asn Leu Lys 20 25 30 TAC GGT GGT ACC GAC ATA GCC GTG ATA GGC CCA CCT TCT AAA GAA AAA 192 Tyr Gly Gly Thr Asp He Ala Val He Gly Pro Pro Ser Lys Glu Lys 35 40 45 TTC CTT AGA ATT AAT TTC CAA AGT TCC CGA GGA ACG GTC TCA CTT GGC 240 Phe Leu Arg He Asn Phe Gin Ser Ser Arg Gly Thr Val Ser Leu Gly 50 55 60 65 CTA AAA CGC GAT AAC TTG TAT GTG GTC GCG TAT CTT GCA ATG GAT AAC 288 Leu Lys Arg Asp Asn Leu Tyr Val Val Ala Tyr Leu Ala Met Asp Asn 70 75 80 ACG AAT GTT AAT CGG GCA TAT TAC TTC AGA TCA GAA ATT ACT TCC GCC 336 Thr Asn Val Asn Arg Ala Tyr Tyr Phe Arg Ser Glu He Thr Ser Ala 85 90 95 GAG TTA ACC GCC CTT TTC CCA GAG GCC ACA ACT GCA AAT CAG AAA GCT 384 Glu Leu Thr Ala Leu Phe Pro Glu Ala Thr Thr Ala Asn Gin Lys Ala 100 105 110 TTA GAA TAC ACA GAA GAT TAT CAG TCG ATC GAA AAG AAT GCC CAG ATA 432 Leu Glu Tyr Thr Glu Asp Tyr Gin Ser He Glu Lys Asn Ala Gin He 115 120 125 ACA CAG GGA GAT AAA TCA AGA AAA GAA CTC GGG TTG GGG ATC GAC TTA 480 Thr Gin Gly Asp Lys Ser Arg Lys Glu Leu Gly Leu Gly He Asp Leu 130 135 140 145 CTT TTG ACG TCC ATG GAA GCA GTG AAC AAG AAG GCA CGT GTG GTT AAA 528 Leu Leu Thr Ser Met Glu Ala Val Asn Lys Lys Ala Arg Val Val Lys 150 155 160 AAC GAA GCT AGG TTT CTG CTT ATC GCT ATT CAA ATG ACA GCT GAG GTA 576 Asn Glu Ala Arg Phe Leu Leu He Ala He Gin Met Thr Ala Glu Val 165 170 175 GCA CGA TTT CGG TAC ATT CAA AAC TTG GTA ACT AAG AAC TTC CCC AAC 624 Ala Arg Phe Arg Tyr He Gin Asn Leu Val Thr Lys Asn Phe Pro Asn 180 185 190 AAG TTC GAC TCG GAT AAC AAG GTG ATT CAA TTT GAA GTC AGC TGG CGT 672 Lys Phe Asp Ser Asp Asn Lys Val He Gin Phe Glu Val Ser Trp Arg 195 200 205 AAG ATT TCT ACG GCA ATA TAC GGA GAT GCC AAA AAC GGC GTG TTT AAT 720 Lys He Ser Thr Ala He Tyr Gly Asp Ala Lys Asn Gly Val Phe Asn 210 215 220 225 AAA GAT TAT GAT TTC GGG TTT GGA AAA GTG AGG CAG GTG AAG GAC TTG 768 Lys Asp Tyr Asp Phe Gly Phe Gly Lys Val Arg Gin Val Lys Asp Leu 230 235 240 CAA ATG GGA CTC CTT ATG TAT TTG GGC AAA CCA AAG 804 Gin Met Gly Leu Leu Met Tyr Leu Gly Lys Pro Lys 245 250 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 804 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..804 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1..804 (D) OTHER INFORMATION: /note= "Nucleotide sequence corresponding to the clone M13 mpl8-G2 in Example l.B.2." (ix) FEATURE: (A) NAME/KEY: mat_peptide (B) LOCATION: 46..804 (D) OTHER INFORMATION: /product= "Saporin" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: GCA TGG ATC CTG CTT CAA TTT TCA GCT TGG ACA ACA ACT GAT GCG GTC 48 Ala Trp He Leu Leu Gin Phe Ser Ala Trp Thr Thr Thr Asp Ala Val -15 -10 -5 1 ACA TCA ATC ACA TTA GAT CTA GTA AAT CCG ACT GCG GGT CAA TAC TCA 96 Thr Ser He Thr Leu Asp Leu Val Asn Pro Thr Ala Gly Gin Tyr Ser 5 10 15 TCT TTT GTG GAT AAA ATC CGA AAC AAC GTA AAG GAT CCA AAC CTG AAA 144 Ser Phe Val Asp Lys He Arg Asn Asn Val Lys Asp Pro Asn Leu Lys 20 25 30 TAC GGT GGT ACC GAC ATA GCC GTG ATA GGC CCA CCT TCT AAA GAT AAA 192 Tyr Gly Gly Thr Asp He Ala Val He Gly Pro Pro Ser Lys Asp Lys 35 40 45 TTC CTT AGA ATT AAT TTC CAA AGT TCC CGA GGA ACG GTC TCA CTT GGC 240 Phe Leu Arg He Asn Phe Gin Ser Ser Arg Gly Thr Val Ser Leu Gly 50 55 60 65 CTA AAA CGC GAT AAC TTG TAT GTG GTC GCG TAT CTT GCA ATG GAT AAC 288 Leu Lys Arg Asp Asn Leu Tyr Val Val Ala Tyr Leu Ala Met Asp Asn 70 75 80 ACG AAT GTT AAT CGG GCA TAT TAC TTC AAA TCA GAA ATT ACT TCC GCC 336 Thr Asn Val Asn Arg Ala Tyr Tyr Phe Lys Ser Glu He Thr Ser Ala 85 90 95 GAG TTA ACC GCC CTT TTC CCA GAG GCC ACA ACT GCA AAT CAG AAA GCT 384 Glu Leu Thr Ala Leu Phe Pro Glu Ala Thr Thr Ala Asn Gin Lys Ala 100 105 110 TTA GAA TAC ACA GAA GAT TAT CAG TCG ATC GAA AAG AAT GCC CAG ATA 432 Leu Glu Tyr Thr Glu Asp Tyr Gin Ser He Glu Lys Asn Ala Gin He 115 120 125 ACA CAG GGA GAT AAA AGT AGA AAA GAA CTC GGG TTG GGG ATC GAC TTA 480 Thr Gin Gly Asp Lys Ser Arg Lys Glu Leu Gly Leu Gly He Asp Leu 130 135 140 145 CTT TTG ACG TTC ATG GAA GCA GTG AAC AAG AAG GCA CGT GTG GTT AAA 528 Leu Leu Thr Phe Met Glu Ala Val Asn Lys Lys Ala Arg Val Val Lys 150 155 160 AAC GAA GCT AGG TTT CTG CTT ATC GCT ATT CAA ATG ACA GCT GAG GTA 576 Asn Glu Ala Arg Phe Leu Leu He Ala He Gin Met Thr Ala Glu Val 165 170 175 GCA CGA TTT AGG TAC ATT CAA AAC TTG GTA ACT AAG AAC TTC CCC AAC 624 Ala Arg Phe Arg Tyr He Gin Asn Leu Val Thr Lys Asn Phe Pro Asn 180 185 190 AAG TTC GAC TCG GAT AAC AAG GTG ATT CAA TTT GAA GTC AGC TGG CGT 672 Lys Phe Asp Ser Asp Asn Lys Val He Gin Phe Glu Val Ser Trp Arg 195 200 205 AAG ATT TCT ACG GCA ATA TAC GGG GAT GCC AAA AAC GGC GTG TTT AAT 720 Lys He Ser Thr Ala He Tyr Gly Asp Ala Lys Asn Gly Val Phe Asn 210 215 220 225 AAA GAT TAT GAT TTC GGG TTT GGA AAA GTG AGG CAG GTG AAG GAC TTG 768 Lys Asp Tyr Asp Phe Gly Phe Gly Lys Val Arg Gin Val Lys Asp Leu 230 235 240 CAA ATG GGA CTC CTT ATG TAT TTG GGC AAA CCA AAG 804 Gin Met Gly Leu Leu Met Tyr Leu Gly Lys Pro Lys 245 250 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 804 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..804 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1..804 (D) OTHER INFORMATION: /note= "Nucleotide sequence corresponding to the clone M13 mpl8-G7 in Example l.B.2." (ix) FEATURE: (A) NAME/KEY: mat_peptide (B) LOCATION: 46..804 (D) OTHER INFORMATION: /product= "Saporin" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: GCA TGG ATC CTG CTT CAA TTT TCA GCT TGG ACA ACA ACT GAT GCG GTC 48 Ala Trp He Leu Leu Gin Phe Ser Ala Trp Thr Thr Thr Asp Ala Val -15 -10 -5 1 ACA TCA ATC ACA TTA GAT CTA GTA AAT CCG ACC GCG GGT CAA TAC TCA 96 Thr Ser He Thr Leu Asp Leu Val Asn Pro Thr Ala Gly Gin Tyr Ser 5 10 15 TCT TTT GTG GAT AAA ATC CGA AAC AAC GTA AAG GAT CCA AAC CTG AAA 144 Ser Phe Val Asp Lys He Arg Asn Asn Val Lys Asp Pro Asn Leu Lys 20 25 30 TAC GGT GGT ACC GAC ATA GCC GTG ATA GGC CCA CCT TCT AAA GAA AAA 192 Tyr Gly Gly Thr Asp He Ala Val He Gly Pro Pro Ser Lys Glu Lys 35 40 45 TTC CTT AGA ATT AAT TTC CAA AGT TCC CGA GGA ACG GTC TCA CTT GGC 240 Phe Leu Arg He Asn Phe Gin Ser Ser Arg Gly Thr Val Ser Leu Gly 50 55 60 65 CTA AAA CGC GAT AAC TTG TAT GTG GTC GCG TAT CTT GCA ATG GAT AAC 288 Leu Lys Arg Asp Asn Leu Tyr Val Val Ala Tyr Leu Ala Met Asp Asn 70 75 80 ACG AAT GTT AAT CGG GCA TAT TAC TTC AGA TCA GAA ATT ACT TCC GCC 336 Thr Asn Val Asn Arg Ala Tyr Tyr Phe Arg Ser Glu He Thr Ser Ala 85 90 95 GAG TTA ACC GCC CTT TTC CCA GAG GCC ACA ACT GCA AAT CAG AAA GCT 384 Glu Leu Thr Ala Leu Phe Pro Glu Ala Thr Thr Ala Asn Gin Lys Ala 100 105 110 TTA GAA TAC ACA GAA GAT TAT CAG TCG ATC GAA AAG AAT GCC CAG ATA 432 Leu Glu Tyr Thr Glu Asp Tyr Gin Ser He Glu Lys Asn Ala Gin He 115 120 125 ACA CAG GGA GAT AAA TCA AGA AAA GAA CTC GGG TTG GGG ATC GAC TTA 480 Thr Gin Gly Asp Lys Ser Arg Lys Glu Leu Gly Leu Gly He Asp Leu 130 135 140 145 CTT TTG ACG TCC ATG GAA GCA GTG AAC AAG AAG GCA CGT GTG GTT AAA 528 Leu Leu Thr Ser Met Glu Ala Val Asn Lys Lys Ala Arg Val Val Lys 150 155 160 AAC GAA GCT AGA TTC CTT CTT ATC GCT ATT CAG ATG ACG GCT GAG GCA 576 Asn Glu Ala Arg Phe Leu Leu He Ala He Gin Met Thr Ala Glu Ala 165 170 175 GCA CGA TTT AGG TAC ATA CAA AAC TTG GTA ATC AAG AAC TTT CCC AAC 624 Ala Arg Phe Arg Tyr He Gin Asn Leu Val He Lys Asn Phe Pro Asn 180 185 190 AAG TTC AAC TCG GAA AAC AAA GTG ATT CAG TTT GAG GTT AAC TGG AAA 672 Lys Phe Asn Ser Glu Asn Lys Val He Gin Phe Glu Val Asn Trp Lys 195 200 205 AAA ATT TCT ACG GCA ATA TAC GGG GAT GCC AAA AAC GGC GTG TTT AAT 720 Lys He Ser Thr Ala He Tyr Gly Asp Ala Lys Asn Gly Val Phe Asn 210 215 220 225 AAA GAT TAT GAT TTC GGG TTT GGA AAA GTG AGG CAG GTG AAG GAC TTG 768 Lys Asp Tyr Asp Phe Gly Phe Gly Lys Val Arg Gin Val Lys Asp Leu 230 235 240 CAA ATG GGA CTC CTT ATG TAT TTG GGC AAA CCA AAG 804 Gin Met Gly Leu Leu Met Tyr Leu Gly Lys Pro Lys 245 250 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 804 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..804 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1..804 (D) OTHER INFORMATION: /note= "Nucleotide sequence corresponding to the clone M13 mpl8-G9 in Example l.B.2." (ix) FEATURE: (A) NAME/KEY: mat_peptide (B) LOCATION: 46..804 (D) OTHER INFORMATION: /product= "Saporin" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: GCA TGG ATC CTG CTT CAA TTT TCA GCT TGG ACA ACA ACT GAT GCG GTC 48 Ala Trp He Leu Leu Gin Phe Ser Ala Trp Thr Thr Thr Asp Ala Val -15 -10 -5 1 ACA TCA ATC ACA TTA GAT CTA GTA AAT CCG ACC GCG GGT CAA TAC TCA 96 Thr Ser He Thr Leu Asp Leu Val Asn Pro Thr Ala Gly Gin Tyr Ser 5 10 15 TCT TTT GTG GAT AAA ATC CGA AAC AAC GTA AAG GAT CCA AAC CTG AAA 144 Ser Phe Val Asp Lys He Arg Asn Asn Val Lys Asp Pro Asn Leu Lys 20 25 30 TAC GGT GGT ACC GAC ATA GCC GTG ATA GGC CCA CCT TCT AAA GAA AAA 192 Tyr Gly Gly Thr Asp He Ala Val He Gly Pro Pro Ser Lys Glu Lys 35 40 45 TTC CTT AGA ATT AAT TTC CAA AGT TCC CGA GGA ACG GTC TCA CTT GGC 240 Phe Leu Arg He Asn Phe Gin Ser Ser Arg Gly Thr Val Ser Leu Gly 50 55 60 65 CTA AAA CGC GAT AAC TTG TAT GTG GTC GCG TAT CTT GCA ATG GAT AAC 288 Leu Lys Arg Asp Asn Leu Tyr Val Val Ala Tyr Leu Ala Met Asp Asn 70 75 80 ACG AAT GTT AAT CGG GCA TAT TAC TTC AGA TCA GAA ATT ACT TCC GCC 336 Thr Asn Val Asn Arg Ala Tyr Tyr Phe Arg Ser Glu He Thr Ser Ala 85 90 95 GAG TTA ACC GCC CTT TTC CCA GAG GCC ACA ACT GCA AAT CAG AAA GCT 384 Glu Leu Thr Ala Leu Phe Pro Glu Ala Thr Thr Ala Asn Gin Lys Ala 100 105 110 TTA GAA TAC ACA GAA GAT TAT CAG TCG ATT GAA AAG AAT GCC CAG ATA 432 Leu Glu Tyr Thr Glu Asp Tyr Gin Ser He Glu Lys Asn Ala Gin He 115 120 125 ACA CAA GGA GAT CAA AGT AGA AAA GAA CTC GGG TTG GGG ATT GAC TTA 480 Thr Gin Gly Asp Gin Ser Arg Lys Glu Leu Gly Leu Gly He Asp Leu 130 135 140 145 CTT TCA ACG TCC ATG GAA GCA GTG AAC AAG AAG GCA CGT GTG GTT AAA 528 Leu Ser Thr Ser Met Glu Ala Val Asn Lys Lys Ala Arg Val Val Lys 150 155 160 GAC GAA GCT AGA TTC CTT CTT ATC GCT ATT CAG ATG ACG GCT GAG GCA 576 Asp Glu Ala Arg Phe Leu Leu He Ala He Gin Met Thr Ala Glu Ala 165 170 175 GCG CGA TTT AGG TAC ATA CAA AAC TTG GTA ATC AAG AAC TTT CCC AAC 624 Ala Arg Phe Arg Tyr He Gin Asn Leu Val He Lys Asn Phe Pro Asn 180 185 190 AAG TTC AAC TCG GAA AAC AAA GTG ATT CAG TTT GAG GTT AAC TGG AAA 672 Lys Phe Asn Ser Glu Asn Lys Val He Gin Phe Glu Val Asn Trp Lys 195 200 205 AAA ATT TCT ACG GCA ATA TAC GGG GAT GCC AAA AAC GGC GTG TTT AAT 720 Lys He Ser Thr Ala He Tyr Gly Asp Ala Lys Asn Gly Val Phe Asn 210 215 220 225 AAA GAT TAT GAT TTC GGG TTT GGA AAA GTG AGG CAG GTG AAG GAC TTG 768 Lys Asp Tyr Asp Phe Gly Phe Gly Lys Val Arg Gin Val Lys Asp Leu 230 235 240 CAA ATG GGA CTC CTT ATG TAT TTG GGC AAA CCA AAG 804 Gin Met Gly Leu Leu Met Tyr Leu Gly Lys Pro Lys 245 250 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: misc_recomb (B) LOCATION: 10..15 (D) OTHER INFORMATION: /standard_name= "Nco I restriction enzyme recognition site" ~ (ix) FEATURE: (A) NAME/KEY: mat_peptide (B) LOCATION: 15..22 (D) OTHER INFORMATION: /product= "N-terminus of Saporin protein" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: CAACAACTGC CATGGTCACA TC 22 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: misc_recomb (B) LOCATION: 11..16 (D) OTHER INFORMATION: /standard_name= "Nco I restriction enzyme recognition site." (ix) FEATURE: (A) NAME/KEY: mat_peρtide (B) LOCATION: 1..10 (D) OTHER INFORMATION: /product= "Carboxy terminus of mature FGF protein" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: GCTAAGAGCG CCATGGAGA 19 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..12 (D) OTHER INFORMATION: /product= "Carboxy terminus of wild type FGF" (ix) FEATURE: (A) NAME/KEY: misc_recomb (B) LOCATION: 13..18 (D) OTHER INFORMATION: /standard_name= "Nco I restriction enzyme recognition site" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: GCT AAG AGC TGACCATGGA GA 21 Ala Lys Ser 1 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 102 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..96 (D) OTHER INFORMATION: /product= "pFGFNcol" /note= "Equals the plasmid pFC80 with native FGF stop codon removed." (ix) FEATURE: (A) NAME/KEY: misc_recomb (B) LOCATION: 29..34 (D) OTHER INFORMATION: /standard_name= "Nco I restriction enzyme recognition site" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: CTT TTT CTT CCA ATG TCT GCT AAG AGC GCC ATG GAG ATC CGG CTG AAT 48 Leu Phe Leu Pro Met Ser Ala Lys Ser Ala Met Glu He Arg Leu Asn 1 5 10 15 GGT GCA GTT CTG TAC CGG TTT TCC TGT GCC GTC TTT CAG GAC TCC TGAAATCTT 102 Gly Ala Val Leu Tyr Arg Phe Ser Cys Ala Val Phe Gin Asp Ser 20 25 30 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1230 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1230 (ix) FEATURE: (A) NAME/KEY: mat_peptide (B) LOCATION: 1..465 (D) OTHER INFORMATION: /product= "bFGF" (ix) FEATURE: (A) NAME/KEY: mat_peptide (B) LOCATION: 472..1230 (D) OTHER INFORMATION: /product= "Saporin" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: ATG GCA GCA GGA TCA ATA ACA ACA TTA CCC GCC TTG CCC GAG GAT GGC 48 Met Ala Ala Gly Ser He Thr Thr Leu Pro Ala Leu Pro Glu Asp Gly 1 5 10 15 GGC AGC GGC GCC TTC CCG CCC GGC CAC TTC AAG GAC CCC AAG CGG CTG 96 Gly Ser Gly Ala Phe Pro Pro Gly His Phe Lys Asp Pro Lys Arg Leu 20 25 30 TAC TGC AAA AAC GGG GGC TTC TTC CTG CGC ATC CAC CCC GAC GGC CGA 144 Tyr Cys Lys Asn Gly Gly Phe Phe Leu Arg He His Pro Asp Gly Arg 35 40 45 GTT GAC GGG GTC CGG GAG AAG AGC GAC CCT CAC ATC AAG CTT CAA CTT 192 Val Asp Gly Val Arg Glu Lys Ser Asp Pro His He Lys Leu Gin Leu 50 55 60 CAA GCA GAA GAG AGA GGA GTT GTG TCT ATC AAA GGA GTG TGT GCT AAC 240 Gin Ala Glu Glu Arg Gly Val Val Ser He Lys Gly Val Cys Ala Asn 65 70 75 80 CGT TAC CTG GCT ATG AAG GAA GAT GGA AGA TTA CTG GCT TCT AAA TGT 288 Arg Tyr Leu Ala Met Lys Glu Asp Gly Arg Leu Leu Ala Ser Lys Cys 85 90 95 GTT ACG GAT GAG TGT TTC TTT TTT GAA CGA TTG GAA TCT AAT AAC TAC 336 Val Thr Asp Glu Cys Phe Phe Phe Glu Arg Leu Glu Ser Asn Asn Tyr 100 105 110 AAT ACT TAC CGG TCA AGG AAA TAC ACC AGT TGG TAT GTG GCA TTG AAA 384 Asn Thr Tyr Arg Ser Arg Lys Tyr Thr Ser Trp Tyr Val Ala Leu Lys 115 120 125 CGA ACT GGG CAG TAT AAA CTT GGA TCC AAA ACA GGA CCT GGG CAG AAA 432 Arg Thr Gly Gin Tyr Lys Leu Gly Ser Lys Thr Gly Pro Gly Gin Lys 130 135 140 GCT ATA CTT TTT CTT CCA ATG TCT GCT AAG AGC GCC ATG GTC ACA TCA 480 Ala He Leu Phe Leu Pro Met Ser Ala Lys Ser Ala Met Val Thr Ser 145 150 155 160 ATC ACA TTA GAT CTA GTA AAT CCG ACC GCG GGT CAA TAC TCA TCT TTT 528 He Thr Leu Asp Leu Val Asn Pro Thr Ala Gly Gin Tyr Ser Ser Phe 165 170 175 GTG GAT AAA ATC CGA AAC AAC GTA AAG GAT CCA AAC CTG AAA TAC GGT 576 Val Asp Lys He Arg Asn Asn Val Lys Asp Pro Asn Leu Lys Tyr Gly 180 185 190 GGT ACC GAC ATA GCC GTG ATA GGC CCA CCT TCT AAA GAA AAA TTC CTT 624 Gly Thr Asp He Ala Val He Gly Pro Pro Ser Lys Glu Lys Phe Leu 195 200 205 AGA ATT AAT TTC CAA AGT TCC CGA GGA ACG GTC TCA CTT GGC CTA AAA 672 Arg He Asn Phe Gin Ser Ser Arg Gly Thr Val Ser Leu Gly Leu Lys 210 215 220 CGC GAT AAC TTG TAT GTG GTC GCG TAT CTT GCA ATG GAT AAC ACG AAT 720 Arg Asp Asn Leu Tyr Val Val Ala Tyr Leu Ala Met Asp Asn Thr Asn 225 230 235 240 GTT AAT CGG GCA TAT TAC TTC AAA TCA GAA ATT ACT TCC GCC GAG TTA 768 Val Asn Arg Ala Tyr Tyr Phe Lys Ser Glu He Thr Ser Ala Glu Leu 245 250 255 ACC GCC CTT TTC CCA GAG GCC ACA ACT GCA AAT CAG AAA GCT TTA GAA 816 Thr Ala Leu Phe Pro Glu Ala Thr Thr Ala Asn Gin Lys Ala Leu Glu 260 265 270 TAC ACA GAA GAT TAT CAG TCG ATC GAA AAG AAT GCC CAG ATA ACA CAG 864 Tyr Thr Glu Asp Tyr Gin Ser He Glu Lys Asn Ala Gin He Thr Gin 275 280 285 GGA GAT AAA AGT AGA AAA GAA CTC GGG TTG GGG ATC GAC TTA CTT TTG 912 Gly Asp Lys Ser Arg Lys Glu Leu Gly Leu Gly He Asp Leu Leu Leu 290 295 300 ACG TTC ATG GAA GCA GTG AAC AAG AAG GCA CGT GTG GTT AAA AAC GAA 960 Thr Phe Met Glu Ala Val Asn Lys Lys Ala Arg Val Val Lys Asn Glu 305 310 315 320 GCT AGG TTT CTG CTT ATC GCT ATT CAA ATG ACA GCT GAG GTA GCA CGA 1008 Ala Arg Phe Leu Leu He Ala He Gin Met Thr Ala Glu Val Ala Arg 325 330 335 TTT AGG TAC ATT CAA AAC TTG GTA ACT AAG AAC TTC CCC AAC AAG TTC 1056 Phe Arg Tyr He Gin Asn Leu Val Thr Lys Asn Phe Pro Asn Lys Phe 340 345 350 GAC TCG GAT AAC AAG GTG ATT CAA TTT GAA GTC AGC TGG CGT AAG ATT 1104 Asp Ser Asp Asn Lys Val He Gin Phe Glu Val Ser Trp Arg Lys He 355 360 365 TCT ACG GCA ATA TAC GGG GAT GCC AAA AAC GGC GTG TTT AAT AAA GAT 1152 Ser Thr Ala He Tyr Gly Asp Ala Lys Asn Gly Val Phe Asn Lys Asp 370 375 380 TAT GAT TTC GGG TTT GGA AAA GTG AGG CAG GTG AAG GAC TTG CAA ATG 1200 Tyr Asp Phe Gly Phe Gly Lys Val Arg Gin Val Lys Asp Leu Gin Met 385 390 395 400 GGA CTC CTT ATG TAT TTG GGC AAA CCA AAG 1230 Gly Leu Leu Met Tyr Leu Gly Lys Pro Lys 405 410 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1230 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1230 (ix) FEATURE: (A) NAME/KEY: mat_peptide (B) LOCATION: 1..465 (D) OTHER INFORMATION: /product= "bFGF" (ix) FEATURE: (A) NAME/KEY: mat_peptide (B) LOCATION: 472..1230 (D) OTHER INFORMATION: /product= "Saporin" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: ATG GCT GCT GGT TCT ATC ACT ACT CTG CCG GCT CTG CCG GAA GAC GGT 48 Met Ala Ala Gly Ser He Thr Thr Leu Pro Ala Leu Pro Glu Asp Gly 1 5 10 15 GGT TCT GGT GCT TTC CCG CCC GGC CAC TTC AAG GAC CCC AAG CGG CTG 96 Gly Ser Gly Ala Phe Pro Pro Gly His Phe Lys Asp Pro Lys Arg Leu 20 25 30 TAC TGC AAA AAC GGG GGC TTC TTC CTG CGC ATC CAC CCC GAC GGC CGA 144 Tyr Cys Lys Asn Gly Gly Phe Phe Leu Arg He His Pro Asp Gly Arg 35 40 45 GTT GAC GGG GTC CGG GAG AAG AGC GAC CCT CAC ATC AAG CTT CAA CTT 192 Val Asp Gly Val Arg Glu Lys Ser Asp Pro His He Lys Leu Gin Leu 50 55 60 CAA GCA GAA GAG AGA GGA GTT GTG TCT ATC AAA GGA GTG TGT GCT AAC 240 Gin Ala Glu Glu Arg Gly Val Val Ser He Lys Gly Val Cys Ala Asn 65 70 75 80 CGT TAC CTG GCT ATG AAG GAA GAT GGA AGA TTA CTG GCT TCT AAA TGT 288 Arg Tyr Leu Ala Met Lys Glu Asp Gly Arg Leu Leu Ala Ser Lys Cys 85 90 95 GTT ACG GAT GAG TGT TTC TTT TTT GAA CGA TTG GAA TCT AAT AAC TAC 336 Val Thr Asp Glu Cys Phe Phe Phe Glu Arg Leu Glu Ser Asn Asn Tyr 100 105 110 AAT ACT TAC CGG TCA AGG AAA TAC ACC AGT TGG TAT GTG GCA TTG AAA 384 Asn Thr Tyr Arg Ser Arg Lys Tyr Thr Ser Trp Tyr Val Ala Leu Lys 115 120 125 CGA ACT GGG CAG TAT AAA CTT GGA TCC AAA ACA GGA CCT GGG CAG AAA 432 Arg Thr Gly Gin Tyr Lys Leu Gly Ser Lys Thr Gly Pro Gly Gin Lys 130 135 140 GCT ATA CTT TTT CTT CCA ATG TCT GCT AAG AGC GCC ATG GTC ACA TCA 480 Ala He Leu Phe Leu Pro Met Ser Ala Lys Ser Ala Met Val Thr Ser 145 150 155 160 ATC ACA TTA GAT CTA GTA AAT CCG ACC GCG GGT CAA TAC TCA TCT TTT 528 He Thr Leu Asp Leu Val Asn Pro Thr Ala Gly Gin Tyr Ser Ser Phe 165 170 175 GTG GAT AAA ATC CGA AAC AAC GTA AAG GAT CCA AAC CTG AAA TAC GGT 576 Val Asp Lys He Arg Asn Asn Val Lys Asp Pro Asn Leu Lys Tyr Gly 180 185 190 GGT ACC GAC ATA GCC GTG ATA GGC CCA CCT TCT AAA GAA AAA TTC CTT 624 Gly Thr Asp He Ala Val He Gly Pro Pro Ser Lys Glu Lys Phe Leu 195 200 205 AGA ATT AAT TTC CAA AGT TCC CGA GGA ACG GTC TCA CTT GGC CTA AAA 672 Arg He Asn Phe Gin Ser Ser Arg Gly Thr Val Ser Leu Gly Leu Lys 210 215 220 CGC GAT AAC TTG TAT GTG GTC GCG TAT CTT GCA ATG GAT AAC ACG AAT 720 Arg Asp Asn Leu Tyr Val Val Ala Tyr Leu Ala Met Asp Asn Thr Asn 225 230 235 240 GTT AAT CGG GCA TAT TAC TTC AAA TCA GAA ATT ACT TCC GCC GAG TTA 768 Val Asn Arg Ala Tyr Tyr Phe Lys Ser Glu He Thr Ser Ala Glu Leu 245 250 255 ACC GCC CTT TTC CCA GAG GCC ACA ACT GCA AAT CAG AAA GCT TTA GAA 816 Thr Ala Leu Phe Pro Glu Ala Thr Thr Ala Asn Gin Lys Ala Leu Glu 260 265 270 TAC ACA GAA GAT TAT CAG TCG ATC GAA AAG AAT GCC CAG ATA ACA CAG 864 Tyr Thr Glu Asp Tyr Gin Ser He Glu Lys Asn Ala Gin He Thr Gin 275 280 285 GGA GAT AAA AGT AGA AAA GAA CTC GGG TTG GGG ATC GAC TTA CTT TTG 912 Gly Asp Lys Ser Arg Lys Glu Leu Gly Leu Gly He Asp Leu Leu Leu 290 295 300 ACG TTC ATG GAA GCA GTG AAC AAG AAG GCA CGT GTG GTT AAA AAC GAA 960 Thr Phe Met Glu Ala Val Asn Lys Lys Ala Arg Val Val Lys Asn Glu 305 310 315 320 GCT AGG TTT CTG CTT ATC GCT ATT CAA ATG ACA GCT GAG GTA GCA CGA 1008 Ala Arg Phe Leu Leu He Ala He Gin Met Thr Ala Glu Val Ala Arg 325 330 335 TTT AGG TAC ATT CAA AAC TTG GTA ACT AAG AAC TTC CCC AAC AAG TTC 1056 Phe Arg Tyr He Gin Asn Leu Val Thr Lys Asn Phe Pro Asn Lys Phe 340 345 350 GAC TCG GAT AAC AAG GTG ATT CAA TTT GAA GTC AGC TGG CGT AAG ATT 1104 Asp Ser Asp Asn Lys Val He Gin Phe Glu Val Ser Trp Arg Lys He 355 360 365 TCT ACG GCA ATA TAC GGG GAT GCC AAA AAC GGC GTG TTT AAT AAA GAT 1152 Ser Thr Ala He Tyr Gly Asp Ala Lys Asn Gly Val Phe Asn Lys Asp 370 375 380 TAT GAT TTC GGG TTT GGA AAA GTG AGG CAG GTG AAG GAC TTG CAA ATG 1200 Tyr Asp Phe Gly Phe Gly Lys Val Arg Gin Val Lys Asp Leu Gin Met 385 390 395 400 GGA CTC CTT ATG TAT TTG GGC AAA CCA AAG 1230 Gly Leu Leu Met Tyr Leu Gly Lys Pro Lys 405 410 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 59 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: AATTCCCCTG TTGACAATTA ATCATCGAAC TAGTTAACTA GTACGCAGCT TGGCTGCAG 59 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 59 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: GTCGACCAAG CTTGGGCATA CATTCAATCA ATTGTTATCT AAGGAAATAC TTACATATG 59

Claims: CLAIMS: 1. An isolated recombinant DNA fragment, comprising a sequence of nucleotides encoding a saporin-containing protein, wherein: the saporin containing protein consists essentially of an N-terminal extension linked to the amino terminus of all or a portion of a saporin protein; and the N-terminal extension and portion of saporin are selected so that the saporin-containing protein is cytotoxic upon internalization by a eukaryotic cell. 2. The DNA fragment of claim 1 , further comprising a promoter region and a transcription terminator region, wherein: the promoter region includes an inducible promoter; the promoter region and the transcription terminator are independently selected from the same or different genes and are are operatively linked to the DNA encoding the saporin-containing protein. 3. The DNA construct of claim 1 or claim 2, wherein the N-terminal extension saporin-containing protein encodes 2 to 15 amino acids in length. 4. The DNA construct of claim 3, wherein the sequence of the 2 to 15 amino acids is the same as the sequence of 2 to 15 amino acids of the native secretion signal sequence of the a saporin protein. 5. The DNA fragment of claim 1 or claim 2, wherein the N-terminal includes a ligand that specifically interacts with a cell surface protein. 6. The DNA fragment of Claim 5, wherein the ligand is basic FGF. 7. The DNA fragment of Claim 2, wherein the promoter region contains the lac promoter operator (lacO). 8. The DNA fragment of claim 2, wherein the promoter is Ipp. 9. The DNA fragment of claim 1 or claim 2, wherein the amino acid sequence of the saporin-containing protein is set forth in SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6 or SEQ ID NO. 7. 10. The DNA fragment of claim 1 or claim 2, wherein the amino acid sequence of the saporin-containing protein is set forth in SEQ ID NO. 12 or SEQ ID NO. 13. 1 1 . The DNA fragment of claim 1 , further comprising DNA encoding a secretion signal sequence operatively linked to the DNA encoding the saporin-containing protein. 12. The DNA fragment of claim 1 1 , wherein the secretion signal is ompA or ompT. 13. The DNA fragment of claim 12, wherein the promoter is the T7 promoter or the lacUVδ promoter. 14. A plasmid, comprising the DNA fragment of any of claims 1-13. 15. The plasmid of claim 14, which is selected from the group consisting of pOMPAG4, pOMPAGI , pOMPAG2, pOMPAG7, and pOMPAG9. 16. The plasmid of claim 14 that is PZ1A, PZ1 B, PZ1 C, or PZID. 17. An E. coli cell transformed with the plasmid of any of claims 14-16. 18. A culture of viable E. coli cells, comprising cells of claim 17. 19. A process for the production of a biologically active saporin- containing protein in JL coli.. comprising culturing the cells of claim 19 under conditions whereby the saporin-containing protein is expressed, and isolating the saporin-containing protein. 20. The process of claim 19, wherein said N-terminal extension contains a ligand. 21. The process of claim 19 or claim 20, wherein said ligand is a growth factor, hormone, or a cell binding domain of an antibody. 22. The process of claim 20 or claim 21 , wherein said ligand is basic fibroblast growth factor (bFGF). 23. An isolated saporin-containing protein, comprising saporin and an N-terminal extension, wherein the saporin-containing protein is cytotoxic upon internalization by a eukaryotic cell. 24. The saporin containing protein of claim 23, comprising the sequence of amino acids set forth in any of SEQ ID NOs. 3-7, 12 and 13. 25. The saporin-containing protein of claim 24, comprising saporin linked to basic fibroblast growth factor via a linker peptide of from 2 to about 12 amino acids.

Inventors: BAIRD J ANDREW, BARTHELEMY ISABEL, LAPPI DOUGLAS A, SOSNOWSKI BARBARA A, BAIRD, J., ANDREW, BARTHELEMY, ISABEL, LAPPI, DOUGLAS, A., SOSNOWSKI, BARBARA, A.
Applicants: BAIRD J ANDREW, BARTHELEMY ISABEL, LAPPI DOUGLAS A, PRIZM PHARMA INC, SOSNOWSKI BARBARA A, WHITTIER INST DIABETES & ENDOC, PRIZM PHARMACEUTICALS, INC., WHITTIER INSTITUTE FOR DIABETES AND ENDOCRINOLOGY
Application year: 1993
Main classification: C12N15
IPC codes: A61K39, C07K1, C07K14, C07K16, C07K19, C12N1, C12N15, C12P21, C12R1